Original Article
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
N Engl J Med 2008; 358:1250-1261March 20, 2008
- Abstract
Background
We sought to identify determinants of health-related quality of life after primary treatment of prostate cancer and to measure the effects of such determinants on satisfaction with the outcome of treatment in patients and their spouses or partners.
Methods
We prospectively measured outcomes reported by 1201 patients and 625 spouses or partners at multiple centers before and after radical prostatectomy, brachytherapy, or external-beam radiotherapy. We evaluated factors that were associated with changes in quality of life within study groups and determined the effects on satisfaction with the treatment outcome.
Results
Adjuvant hormone therapy was associated with worse outcomes across multiple quality-of-life domains among patients receiving brachytherapy or radiotherapy. Patients in the brachytherapy group reported having long-lasting urinary irritation, bowel and sexual symptoms, and transient problems with vitality or hormonal function. Adverse effects of prostatectomy on sexual function were mitigated by nerve-sparing procedures. After prostatectomy, urinary incontinence was observed, but urinary irritation and obstruction improved, particularly in patients with large prostates. No treatment-related deaths occurred; serious adverse events were rare. Treatment-related symptoms were exacerbated by obesity, a large prostate size, a high prostate-specific antigen score, and older age. Black patients reported lower satisfaction with the degree of overall treatment outcomes. Changes in quality of life were significantly associated with the degree of outcome satisfaction among patients and their spouses or partners.
Conclusions
Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function. These changes influenced satisfaction with treatment outcomes among patients and their spouses or partners.
Media in This Article
Figure 1
Changes in Quality of Life after Primary Treatment for Prostate Cancer.Table 1
Characteristics of the Patients.Article Activity
- Article
Assessment of the outcome of prostate-cancer treatment entails measuring not only the duration of survival but also the health-related quality of life.1,2 Early studies of patient-reported outcomes of prostatectomy or conventional radiotherapy found concern about urinary incontinence, bowel function, and sexual activity.3-5 However, little is known about the quality of life after newer treatments such as brachytherapy and androgen-suppression therapy as an adjunct to radiotherapy.6-8 Single-institution studies and one retrospective analysis of a longitudinal, multicenter cohort used instruments that had been developed for assessment of standard external-beam radiotherapy and prostatectomy to probe the quality of life after brachytherapy,9-11 but prospective, multiregional studies of the quality of life after brachytherapy, radiotherapy (including hormonal treatment), and prostatectomy have been lacking.
There is no consensus regarding the best way to assemble the distinct domains of the quality of life of cancer survivors into a unified end point.2 Donabedian12,13 and others14,15 proposed that satisfaction with outcome is the ultimate arbiter, but most measures of satisfaction focus on cancer care, rather than outcome. We sought to characterize the quality of life after contemporary treatments for prostate cancer, to identify factors influencing this outcome, and to determine how the quality of life relates to overall satisfaction with the outcome of treatment from the perspective of the patient and his spouse or partner.
Methods
Patients
Patients were enrolled from March 2003 to March 2006 after approval by the institutional review boards at nine university-affiliated hospitals. Men with previously untreated stage T1 to T2 prostate cancer who had elected prostatectomy, brachytherapy, or external-beam radiotherapy as primary treatment and their spouses (partners) were eligible. All patients and their partners provided written informed consent. The group we studied consisted of 1201 such patients who had completed a pretreatment evaluation and 625 partners.
Data Collection and Follow-up
Patient-reported outcome measures, including the Expanded Prostate Cancer Index Composite (EPIC-26) and Service Satisfaction Scale for Cancer Care (SCA),16-19 were collected by a third-party phone-survey facility before treatment and at 2, 6, 12, and 24 months after the start of treatment. (For details regarding the interview process, see the Supplementary Appendix, available with the full text of this article at www.nejm.org.) The Service Satisfaction Scale for Cancer Care for Partners (SCA-P) and EPIC–Partner modules were administered to partners at 2, 6, 12, and 24 months after the start of the patient's treatment. At the time of this analysis, patients had been followed for a median of 30 months. Of the 1201 patients, 112 did not complete follow-up for the following reasons: 12 died (from causes unrelated to prostate cancer or its treatment), 84 withdrew from the study, and 16 missed two consecutive interviews.
Treatment
Brachytherapy was performed with the use of a transperineal technique with permanent low-dose-rate isotopes.20 Brachytherapy was administered alone in 271 patients; 35 received brachytherapy in combination with external-beam radiotherapy, androgen-suppression therapy, or both. External-beam radiotherapy was accomplished by intensity-modulated radiotherapy or highly conformal techniques7 by itself in 202 patients and with androgen-suppression therapy in 90 patients. Pretreatment interviews were conducted before the start of hormonal treatment. Prostatectomy was performed with the use of retropubic, laparoscopic, or robot-assisted techniques.21-23 A total of 561 patients underwent nerve-sparing procedures, and 41 underwent procedures that were not nerve-sparing; surgical-plan data were incomplete for 1 patient. There were three serious adverse events (two patients with pulmonary emboli and one with a rectourethral fistula). There were no treatment-related deaths. (For details regarding treatment and acute adverse effects, see the Supplementary Appendix.)
Statistical Analysis
We assessed differences in baseline demographic characteristics and variables related to cancer severity according to study group with the use of generalized chi-square and nonparametric Wilcoxon rank-sum tests. Scores for patient-reported outcomes, as measured by EPIC-26 and SCA, were calculated as described previously.16-19 Resulting domain scores for both instruments are on a 0 to 100 scale, with higher values representing a more favorable health-related quality of life or outcome satisfaction. To account for correlation among repeated measures from the same patient, the longitudinal study was analyzed with the use of linear generalized estimating equations (GEE), a multivariate analogue of linear regression for longitudinal data.24,25
First, to assess which quality-of-life domains were affected over time by a specific type of treatment, we evaluated the time profiles of EPIC quality-of-life scores, stratified according to study group, with the use of models containing indicators for each post-treatment time point to assess whether the average score at each time point differed significantly from that at baseline. Standard errors were calculated with the use of the GEE sandwich method to account for within-patient correlation. A clinically relevant change in the quality of life (or a minimum important change) was defined as a difference from baseline to follow-up that exceeded half a standard deviation of the baseline value.1,26
Second, to assess baseline factors that affected changes in quality of life within study groups, we evaluated the independent effects of factors with respect to patients and treatments on changes from baseline by fitting linear regression GEE models for the repeated-measures data. The baseline quality-of-life score was included in each model as a covariate. (See the Supplementary Appendix for additional details regarding model building and other analyses.)
Third, to determine whether changes in quality of life were distressing to the partner, we evaluated the association between the patient's change in quality of life and distress in his partner due to the patient's symptoms at 1 year with the use of Spearman's rank correlation. (For data on survey items that queried spousal distress, see the Supplementary Appendix.)
Fourth, to assess the relative effect of various domain changes of quality of life on overall outcome, we assessed the relationship between the patient's change in quality of life and satisfaction with treatment outcome at 1 year among patients and partners with the use of Spearman's rank correlation and linear regression models.24,25,27 Finally, to identify baseline factors that affected outcome satisfaction, we assessed the relationship between baseline covariates and satisfaction with treatment outcome with the use of linear regression models. Analyses were performed with the use of SAS software. A two-sided P value of less than 0.05 was considered to indicate statistical significance.
Results
Patients
Table 1Table 1
Characteristics of the Patients. shows the characteristics of the patients and baseline differences among the study groups. The median age of the patients was 63 years (range, 38 to 84). The 625 enrolled partners (99% of whom were female) were, on average, younger than the patients (median age, 59; range, 23 to 89; P<0.001). Nine percent of patients and 7% of their partners were black. The number of coexisting illnesses was greatest among patients in the radiotherapy group, intermediate among those in the brachytherapy group, and least in the prostatectomy group. The severity of patients' cancer was greatest in the radiotherapy group, intermediate in the prostatectomy group, and least in the brachytherapy group. Recurrence of prostate cancer was detected in only 14 patients (1%) during follow-up.Health-related quality of life was evaluated primarily as the change over time, stratified according to study group, in domains of sexual function, urinary incontinence, urinary irritation or obstruction, urinary function, bowel or rectal function, and vitality or hormonal function (Figure 1Figure 1
Changes in Quality of Life after Primary Treatment for Prostate Cancer. and Table 2Table 2
Percent of Patients Reporting Specific Levels of Distress or Dysfunction for Each Quality-of-Life Domain, as Queried on the EPIC-26 Survey.). Sexual quality of life was affected in each group (Figure 1A, 1B, and 1C; P<0.001 for the change from baseline to follow-up in each study group). Among patients who underwent prostatectomy, nerve-sparing procedures were associated with better recovery of sexual quality of life than were procedures that were not nerve-sparing. Among patients who received external-beam radiotherapy, recovery of sexual function was worse in patients who received androgen-suppression therapy than in those who received radiotherapy alone (Table 3Table 3
Factors That Were Associated with Changes in the Quality-of-Life Score after Treatment.). Factors that were associated with worse sexual function after treatment, as compared with baseline, were an older age, a large prostate size, and a high pretreatment prostate-specific-antigen (PSA) score. Changes in the patient's sexual quality of life were reflected in reports from his partner. Distress that was related to the patient's erectile dysfunction was reported by 44% of partners in the prostatectomy group, 22% of those in the radiotherapy group, and 13% of those in the brachytherapy group (Table 4Table 4
Problems Reported by 543 Patients and Their Partners Regarding Symptoms and the Association between Changes in Patients' Quality-of-Life Scores and Levels of Distress Reported by Their Partners 1 Year after Treatment., and the Supplementary Appendix).Urinary incontinence was at its worst by 2 months after surgery and then improved in most patients. Factors that were associated with worse incontinence were an older age, black race, and a high PSA score at diagnosis (Figure 1 and Table 3). In contrast, mean scores on urinary irritation or obstruction improved after prostatectomy. Effects of radiotherapy on urinary symptoms had resolved at 12 months and improved over baseline at 24 months. Patients in the brachytherapy group reported significant detriments in urinary irritation or obstruction and incontinence as compared with baseline (P<0.001). Incontinence after brachytherapy was reported by 4 to 6% of patients at 1 to 2 years after treatment. Eighteen percent of patients in the brachytherapy group, 11% of those in the radiotherapy group, and 7% of those in the prostatectomy group reported having moderate or worse distress from overall urinary symptoms at 1 year (Table 2).
Large prostate size and hormonal treatment exacerbated urinary irritation after brachytherapy or radiotherapy, whereas large prostate size at baseline was associated with improvement in urinary irritation after prostatectomy (Table 3). At 1 year, 5% of partners reported being bothered by the patient's incontinence after prostatectomy or brachytherapy, whereas 7% of partners in the brachytherapy group and 3% each in the radiotherapy group and the prostatectomy group reported being bothered by the patient's symptoms of urinary obstruction, such as urinary frequency (Table 4 and the Supplementary Appendix).
Brachytherapy and radiotherapy were both associated with a reduced quality of life related to bowel function early after treatment, and the change lasted for a year or more (Figure 1). Rectal urgency, frequency, pain, fecal incontinence, or hematochezia caused distress related to bowel function in 9% of patients a year after radiotherapy or brachytherapy (Table 2). No substantive change in bowel symptoms was detected after prostatectomy (Figure 1). The reported bowel symptoms were associated with spousal distress: 5% in the radiotherapy group and 4% in the brachytherapy group reported being bothered by the patient's bowel symptoms (Table 4).
Vitality and other outcomes related to hormonal therapy (such as fatigue, weight change, gynecomastia, depression, and hot flashes) were worse after radiotherapy or brachytherapy among patients who received hormonal treatment (90 patients in the radiotherapy group and 21 in the brachytherapy group), as compared with baseline (Figure 1 and Table 2). After radiotherapy, these symptoms persisted for up to 2 years (despite <1 year of treatment in 94% of men who received androgen-suppression therapy). Obesity, hormone therapy, and prostate size were each associated with worse quality-of-life scores related to vitality or hormonal function (Table 3). Overall, 10 to 19% of patients or their partners reported being distressed by symptoms attributable to hormonal therapy (Table 2 and Table 4).
We also examined the relationship between quality-of-life changes in patients or their partners and satisfaction with the overall outcome of treatment. Changes in each of the five quality-of-life domains, as measured by EPIC, were associated with overall outcome satisfaction among both patients and their partners in bivariate analyses (Table 5Table 5
Association between Changes in Quality-of-Life Scores and Satisfaction Regarding Treatment Outcome among Patients and Their Partners at 1 Year.). Multivariable analysis showed that, in descending significance, symptoms related to sexual function, vitality, and urinary function were independently associated with outcome satisfaction among patients. The patient's quality of life related to sexual function was also significantly associated with satisfaction in the partner. Analysis of baseline factors in patients showed that blacks were significantly less satisfied with their overall treatment outcome than were patients of other racial backgrounds (P=0.04).Discussion
Each of three common primary therapies for prostate cancer showed a unique pattern of changes in quality of life related to urinary symptoms, sexual and bowel function, and vitality or hormonal function. Adjuvant hormone therapy exacerbated the adverse effects of radiotherapy or brachytherapy, whereas nerve-sparing surgical procedures mitigated the adverse effects of prostatectomy. Factors that were associated with worse patient-reported outcomes were obesity, a large prostate size, a high pretreatment PSA score, an older age, and black race. The adverse effect of obesity, which was previously linked to urinary incontinence in a single-institution study,28 also exacerbated symptoms related to vitality and hormonal function after radiotherapy or brachytherapy.
Previous multicenter studies that characterized the quality of life after primary therapy for prostate cancer include the Prostate Cancer Outcomes Study (PCOS),4 which relied on a recall of pretreatment quality of life to study the effects of prostatectomy and conventional external-beam radiotherapy, and longitudinal surveys of a limited subgroup of patients in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study.11 Brachytherapy was not evaluated in PCOS, whereas quality-of-life analyses in CaPSURE evaluated a small subgroup of patients, did not measure symptoms related to urinary irritation or hormonal treatment, and had a suboptimal rate of survey response. Our observation that patients who received brachytherapy had symptoms related to sexual or bowel function and urinary irritation or obstruction corroborates effects that were previously noted in single-institution studies.9,10,29,30 Moreover, we observed an association between brachytherapy and both urinary incontinence and reduced vitality.
Previous studies have shown that long-term, primary hormonal therapy is associated with quality-of-life effects.31 We observed that androgen suppression of limited duration, when administered as an adjunct to radiotherapy or brachytherapy, was also associated with long-lasting symptoms involving sexuality and vitality. Notwithstanding the survival benefit of androgen deprivation in randomized clinical trials involving high-risk patients with prostate cancer,8 our findings mitigate enthusiasm for adjuvant hormonal therapy in the setting of disease of low or intermediate risk.
Urinary irritation and obstruction improved after prostatectomy. This observation validates an effect similar to that reported in one single-institution series.32 A Swedish randomized trial, comparing prostatectomy with watchful waiting, also showed fewer obstructive urinary problems among patients who underwent prostatectomy, though the patients' pretreatment values were not evaluated.33
Benefits of nerve-sparing techniques on sexual recovery after prostatectomy have been reported in several high-volume single-surgeon series.34-36 In our multicenter study, we also observed better recovery of sexual function among patients undergoing nerve-sparing procedures than among those who did not undergo nerve-sparing procedures, even after adjustment for pretreatment sexual function. Previous multicenter studies may not have detected benefits of nerve-sparing procedures because of differences in surgical technique, limited sample size, or retrospective design. 4,9,37-39
Previous studies of satisfaction with prostate-cancer care have focused predominantly on treatment, rather than outcome.1,40-43 We found that changes in quality of life were significantly related to satisfaction with overall outcome among both patients and their partners. Black patients were less satisfied with the treatment outcome, despite having received care at the same high-volume institutions as did other patients.
Treatment-related changes in quality of life among patients caused distress in their partners. A previous multicenter trial of chemotherapy for recurrent prostate cancer showed that a patient's therapy had an effect on the well-being of the patient's spouse or partner.44 Our study showed that the level of spousal distress arising from a patient's sexual and urinary symptoms after primary prostate-cancer treatment was also associated with the partner's level of satisfaction with the treatment outcome. These findings confirm those of single-institution studies suggesting that patients' urinary or sexual symptoms are problematic for their partners.45,46
Limitations of our study include the lack of randomization to treatment and hence the possibility that unmeasured selection factors may have influenced the outcomes. Therefore, our analyses are appropriate only for expectations with respect to outcome within study groups and not for a comparison among treatments. The follow-up period of 2 years is relatively short, and measures of quality of life may change further with longer follow-up. Although black patients reported less favorable outcomes than did other patients (despite ostensibly similar care settings), we could not determine whether these differences in outcome reflected disparities in the quality of care, in the expectations of patients, or in cancer biology. Further study will be required to answer these questions.
In conclusion, our measurement of satisfaction with the overall outcome of cancer treatment was sensitive to divergent changes in quality of life of patients and their partners and can provide a unified assessment of the quality of care for patients with prostate cancer.
Supported by a grant (R01-CA95662, to Dr. Sanda) from the National Institutes of Health.
Dr. Sanda reports serving on advisory panels for Amgen and GTx; Dr. Michalski, receiving consulting fees from Envisioneering, serving on advisory panels for Envisioneering and Brachyscience, and providing expert opinion on radiation toxicity; Dr. Greenfield, holding a copyright for the Service Satisfaction Scale 30, from which the SCA was derived; Dr. Kibel, receiving consulting fees from Sanofi-Aventis, AstraZeneca, and Envisioneering; Dr. Kuban, serving on an advisory panel for Calypso Medical Technologies and having an equity interest in Immtech International; Dr. Wood, receiving consulting fees from Cell Genesys and lecture fees from Intuitive Surgical; Dr. Shah, receiving consulting fees from Intuitive Surgical and Gerson-Lehman Consulting; and Dr. Wei, receiving consulting fees from Sanofi-Aventis and Gen Probe, lecture fees from AMS, and grant support from Sanofi-Aventis and Envisioneering. No other potential conflict of interest relevant to this article was reported.
We thank Angela Titsworth, Valerie Stevenson, and Marsha Jessup of the Data Coordinating Center and Jill Hardy of the Phone Interview Facility for their expert project management; the many clinical-site coordinators for their exceptional professionalism in study enrollment, data collection, and regulatory support; Ruth Coburn and the many other research administrators at each site for their support of grant management and regulatory concerns; the many urologists and radiation oncologists who facilitated the identification of study candidates from among their patients; and the participating patients and their partners.
Source Information
From the Departments of Surgery (M.G.S.) and Radiation Oncology (I.K.), Beth Israel Deaconess Medical Center and Harvard Medical School, and the Department of Biostatistics (X.L.), School of Public Health, Harvard University, Boston; Biostatistics Core (R.L.D.) and the Departments of Radiation Oncology (H.M.S.) and Urology (D.W., N.S., J.T.W.), School of Medicine, and School of Nursing (L.N.), University of Michigan, Ann Arbor; the Departments of Radiation Oncology (J.M.) and Urology (A.K.), Washington University, St. Louis; the Office for Survey Research, Institute for Public Policy and Social Research, Michigan State University, East Lansing (L.H.); Alcohol Research Group, Public Health Institute, Emeryville, CA (T.K.G.); the Departments of Urology (M.S.L., C.S.S.) and Health Services (M.S.L.), UCLA Center for Health Sciences, Los Angeles; the Departments of Radiation Oncology (A.M., J.C.) and Urology (E.K.), Cleveland Clinic Hospitals, Cleveland; and the Departments of Urology (L.L.P.) and Radiation Oncology (D.K.), M.D. Anderson Cancer Center, Houston.
Address reprint requests to Dr. Sanda at the Division of Urology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Rabb 440, Boston, MA 02215, or at msanda@bidmc.harvard.edu.
- References
References
1
Barry MJ . Quality of life and prostate cancer treatment. J Urol 1999;162:407-407
CrossRef | Web of Science | Medline2
Payment, and performance improvement programs: moving forward — what should be measured? In: Institute of Medicine, Committee on Redesigning Health Insurance Performance Measures. Performance measurement: accelerating improvement. Washington, DC: National Academies Press, 2006:71-94.
3
Litwin MS ,Hays RD ,Fink A , et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-135
CrossRef | Web of Science | Medline4
Potosky AL ,Legler J ,Albertsen PC , et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-1592
CrossRef | Web of Science | Medline5
Madalinska JB ,Essink-Bot ME ,de Koning HJ ,Kirkels WJ ,van der Maas PJ ,Schroder FH . Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619-1628
Web of Science | Medline6
Lee WR ,Moughan J ,Owen JB ,Zelefsky MJ . The 1999 Patterns of Care Study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 2003;98:1987-1994
CrossRef | Web of Science | Medline7
Shipley WU ,Thames HD ,Sandler HM , et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-1604
CrossRef | Web of Science | Medline8
D'Amico AV ,Manola J ,Loffredo M ,Renshaw AA ,DellaCroce A ,Kantoff PW . 6-Month androgen suppression plus radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004;292:821-827
CrossRef | Web of Science | Medline9
Talcott JA ,Manola J ,Clark JA , et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003;21:3979-3986
CrossRef | Web of Science | Medline10
Brandeis JM ,Litwin MS ,Burnison CM ,Reiter RE . Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163:851-857
CrossRef | Web of Science | Medline11
Downs TM ,Sadetsky N ,Pasta DJ , et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer -- data from CaPSURE. J Urol 2003;170:1822-1827
CrossRef | Web of Science | Medline12
Donabedian A . Evaluating the quality of medical care. Milbank Mem Fund Q 1966;44:Suppl:166-206
CrossRef | Medline13
Donabedian A . The quality of medical care. Science 1978;200:856-864
CrossRef | Web of Science | Medline14
Ware JE Jr ,Snyder MK ,Wright WR ,Davies AR . Defining and measuring patient satisfaction with medical care. Eval Program Plann 1983;6:247-263
CrossRef | Medline15
Cleary PD ,McNeil BJ . Patient satisfaction as an indicator of quality care. Inquiry 1988;25:25-36
Web of Science | Medline16
Wei JT ,Dunn RL ,Litwin MS ,Sandler HM ,Sanda MG . Development and validation of the Expanded Prostate cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905
CrossRef | Web of Science | Medline17
Miller DC ,Sanda MG ,Dunn RL , et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23:2772-2780
CrossRef | Web of Science | Medline18
Greenfield TK ,Attkisson CC . Steps toward a multifactorial satisfaction scale for primary care and mental health services. Eval Prog Plann 1989;12:271-278
CrossRef | Web of Science19
Shah NL ,Dunn RL ,Greenfield TK , et al. Development and validation of a novel instrument to measure patient satisfaction in multiple dimensions of urological cancer care quality. J Urol 2003;169:Suppl:11-11
CrossRef | Web of Science20
Blasko JC ,Mate T ,Sylvester JE ,Grimm PD ,Cavanagh W . Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94
CrossRef | Web of Science | Medline21
Walsh PC. Radical retropubic prostatectomy. In: Walsh PC, Gittes RE, Perlmutter AD, Stamey TA, eds. Campbell's textbook of urology. 5th ed. Philadelphia: W.B. Saunders, 1986:2754-75.
22
Guillonneau B ,Vallancien G . Laparoscopic radical prostatectomy: the Montsouris technique. J Urol 2000;163:1643-1649
CrossRef | Web of Science | Medline23
Menon M ,Tewari A . Robotic radical prostatectomy and the Vattikuti Urology Institute technique: an interim analysis of results and technical points. Urology 2003;61:Suppl 1:15-20
CrossRef | Web of Science | Medline24
Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford, England: Oxford University Press, 2002.
25
Generalized estimating equations (GEE). In: Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal data analysis: Wiley series in probability and statistics. New York: John Wiley, 2004:291-321.
26
Norman GR ,Sloan JA ,Wyrwich KW . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592
CrossRef | Web of Science | Medline27
McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall, 1989.
28
Eastham JA ,Kattan MW ,Rogers E , et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156:1707-1713
CrossRef | Web of Science | Medline29
Davis JW ,Kuban DA ,Lynch DF ,Schellhammer PF . Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166:947-952
CrossRef | Web of Science | Medline30
Wei JT ,Dunn RL ,Sandler HM , et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-566
CrossRef | Web of Science | Medline31
Potosky AL ,Knopf K ,Clegg LX , et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-3757
Web of Science | Medline32
Lepor H ,Kaci L . The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using validated self-administered outcome instruments. J Urol 2004;171:1216-1219
CrossRef | Web of Science | Medline33
Steineck G ,Helgesen F ,Adolfsson J , et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796
Full Text | Web of Science | Medline34
Quinlan DM ,Epstein JI ,Carter BS ,Walsh PC . Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991;145:998-1002
Web of Science | Medline35
Catalona WJ ,Carvalhal GF ,Mager DE ,Smith DS . Potency, continence, and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-438
CrossRef | Web of Science | Medline36
Rabbani F ,Stapleton AMF ,Kattan MW ,Wheeler TM ,Scardino PT . Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164:1929-1934
CrossRef | Web of Science | Medline37
Stanford JL ,Feng Z ,Hamilton AS , et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-360
CrossRef | Web of Science | Medline38
Litwin MS ,Flanders SC ,Pasta DJ ,Stoddard ML ,Lubeck DP ,Henning JM . Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Urology 1999;54:503-508
CrossRef | Web of Science | Medline39
Lubeck DP ,Litwin MS ,Henning JM , et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology 1996;48:773-777
CrossRef | Web of Science | Medline40
Kahn KL ,Malin JL ,Adams J ,Ganz PA . Developing a reliable, valid, and feasible plan for quality-of-care measurement for cancer: how should we measure? Med Care 2002;40:Suppl:III73-III85
CrossRef | Medline41
Carvalhal GF ,Smith DS ,Ramos C , et al. Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. J Urol 1999;162:113-118
CrossRef | Web of Science | Medline42
Lubeck DP ,Litwin MS ,Henning JM ,Mathias SD ,Bloor L ,Carroll PR . An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE. Am J Manag Care 2000;6:70-76
Web of Science | Medline43
Hoffman RM ,Hunt WC ,Gilliland FD ,Stephenson RA ,Potosky AL . Patient satisfaction with treatment decisions for clinically localized prostate carcinoma: results from the Prostate Cancer Outcomes Study. Cancer 2003;97:1653-1662
CrossRef | Web of Science | Medline44
Kornblith AB ,Herndon JE II ,Zuckerman E ,Godley PA ,Savarese D ,Vogelzang NJ . The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001;12:633-641
CrossRef | Web of Science | Medline45
Harden J ,Schafenacker A ,Northouse L , et al. Couples' experiences with prostate cancer: focus group research. Oncol Nurs Forum 2002;29:701-709
CrossRef | Medline46
Soloway CT ,Soloway MS ,Kim SS ,Kava BK . Sexual, psychological and dyadic qualities of the prostate cancer `couple.' BJU Int 2005;95:780-785
CrossRef | Web of Science | Medline
- Citing Articles (318)
Citing Articles
1
Joaquim Bellmunt, Gerhardt Attard, Amit Bahl, Hartwig Huland, Laurence Klotz, Deborah Kuban, Stéphane Oudard, William Watson. (2012) Advances in the management of high-risk localised and metastatic prostate cancer. BJU International 109, 8-13
CrossRef2
Stacy Loeb, E. Jeffrey Metter, Donghui Kan, Kimberly A. Roehl, William J. Catalona. (2012) Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Internationalno-no
CrossRef3
John J. Coen, Jonathan J. Paly, Andrzej Niemierko, Elizabeth Weyman, Anita Rodrigues, William U. Shipley, Anthony L. Zietman, James A. Talcott. (2012) Long-Term Quality of Life Outcome After Proton Beam Monotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 82:2, e201-e209
CrossRef4
Dionysios Mitropoulos, Walter Artibani, Markus Graefen, Mesut Remzi, Morgan Rouprêt, Michael Truss. (2012) Reporting and Grading of Complications After Urologic Surgical Procedures: An ad hoc EAU Guidelines Panel Assessment and Recommendations. European Urology 61:2, 341-349
CrossRef5
Roderick C.N. van den Bergh, Ida J. Korfage, Monique J. Roobol, Chris H. Bangma, Harry J. de Koning, Ewout W. Steyerberg, Marie-Louise Essink-Bot. (2012) Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Internationalno-no
CrossRef6
J.P. Ciezki, I.-C.J. Hsu, M. Abdel-Wahab, V.E. Arterbery, S.J. Frank, J.L. Mohler, B.J. Moran, S.A. Rosenthal, C.J. Rossi, Y. Yamada, G. Merrick. (2012) American College of Radiology Appropriateness Criteria® — Locally Advanced (High-risk) Prostate Cancer. Clinical Oncology 24:1, 43-51
CrossRef7
Eeva Harju, Anja Rantanen, Marja-Terttu Tarkka, Päivi Åstedt-Kurki. (2012) Perceived family health in persons with prostate cancer and their family members. Journal of Clinical Nursing 21:3-4, 544-554
CrossRef8
Xavier Hurtes, Morgan Rouprêt, Christophe Vaessen, Helder Pereira, Benjamin Faivre d'Arcier, Luc Cormier, Franck Bruyère. (2012) Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Internationalno-no
CrossRef9
Louis Potters, Lucille Lee. 2012. Image-Guided Prostate Brachytherapy. , 1371-1375.
CrossRef10
Giorgio Gandaglia, Nazareno Suardi, Andrea Gallina, Umberto Capitanio, Firas Abdollah, Andrea Salonia, Luciano Nava, Renzo Colombo, Giorgio Guazzoni, Patrizio Rigatti, Francesco Montorsi, Alberto Briganti. (2012) Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. The Journal of Urology 187:2, 569-574
CrossRef11
Michael E. Galbraith, Laura Hays, Tanya Tanner. (2012) What Men Say About Surviving Prostate Cancer: Complexities Represented in a Decade of Comments. Clinical Journal of Oncology Nursing 16:1, 65-72
CrossRef12
M. Perl, A. Waldmann, R. Pritzkuleit, A. Katalinic. (2012) Zeitlicher Verlauf der Lebensqualität nach Prostatakarzinom. Der Urologe
CrossRef13
M T King, R Viney, D P Smith, I Hossain, D Street, E Savage, S Fowler, M P Berry, M Stockler, P Cozzi, P Stricker, J Ward, B K Armstrong. (2012) Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer
CrossRef14
Leslie R. Schover, Andrea L. Canada, Ying Yuan, Dawen Sui, Leah Neese, Rosell Jenkins, Michelle M. Rhodes. (2012) A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 118:2, 500-509
CrossRef15
Eric A. Klein, Ian M. Thompson. (2012) Chemoprevention of prostate cancer: an updated view. World Journal of Urology
CrossRef16
Rowan G Casey, Niall M Corcoran, S Larry Goldenberg. (2012) Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian Journal of Andrology
CrossRef17
(2012) Survey of Endourology. Journal of Endourology120104064705002
CrossRef18
Dirk Vordermark. (2012) Editorial Comment. The Journal of Urology 187:1, 123
CrossRef19
Shaun Kilminster, Stig Müller, Mani Menon, Jean V. Joseph, David J. Ralph, Hiten R.H. Patel. (2012) Predicting erectile function outcome in men after radical prostatectomy for prostate cancer. BJU Internationalno-no
CrossRef20
Florian R. Schroeck, Tracey L. Krupski, Suzanne B. Stewart, Lionel L. Bañez, Leah Gerber, David M. Albala, Judd W. Moul. (2012) Pretreatment Expectations of Patients Undergoing Robotic Assisted Laparoscopic or Open Retropubic Radical Prostatectomy. The Journal of Urology
CrossRef21
Frances M Alba, Run Wang. (2012) Can erectile function be predicted after prostate cancer treatment?. Asian Journal of Andrology 14:1, 134-135
CrossRef22
John J. Coen, Anthony L. Zietman, Carl J. Rossi, Joseph A. Grocela, Jason A. Efstathiou, Yan Yan, William U. Shipley. (2012) Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis. International Journal of Radiation Oncology*Biology*Physics 82:1, e25-e31
CrossRef23
Simon P. Kim, R. Jeffrey Karnes. (2012) An Editorial Response to the USPTF. Journal of Men's Health
CrossRef24
Ravi Parikh, David J. Sher. (2012) Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer. Cancer 118:1, 258-267
CrossRef25
Trustin Domes, Eric Chung, Ling DeYoung, Natalie MacLean, Tariq Al-Shaiji, Gerald Brock. (2012) Clinical Outcomes of Intracavernosal Injection in Postprostatectomy Patients: A Single-center Experience. Urology 79:1, 150-155
CrossRef26
Xinglei Shen, Nicholas G Zaorsky, Mark V Mishra, Kathleen A Foley, Terry Hyslop, Sarah Hegarty, Laura T Pizzi, Adam P Dicker, Timothy N Showalter. (2012) Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology 8:1, 37-54
CrossRef27
Nancy P. Mendenhall, Zuofeng Li, Bradford S. Hoppe, Robert B. Marcus, William M. Mendenhall, R. Charles Nichols, Christopher G. Morris, Christopher R. Williams, Joseph Costa, Randal Henderson. (2012) Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 82:1, 213-221
CrossRef28
Alvin C. Goh, Marc A. Kowalkowski, Donald E. Bailey Jr, Meredith W. Kazer, Sara J. Knight, David M. Latini. (2012) Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. BJU Internationalno-no
CrossRef29
L. Alechinsky, V. Phé, D.R. Yates, V. Bourgade, J. Parra, F. Richard, E. Chartier-Kastler, M.-O. Bitker, M. Rouprêt. (2012) Implantation asynchrone d’une prothèse pénienne (AMS 700) chez des patients avec un sphincter urinaire artificiel (AMS 800) : quels sont les résultats fonctionnels de l’AMS 1500 ?. Progrès en Urologie
CrossRef30
Nasiruddin Mohammed, Larry Kestin, Mihai Ghilezan, Daniel Krauss, Frank Vicini, Donald Brabbins, Gary Gustafson, Hong Ye, Alavaro Martinez. (2012) Comparison of Acute and Late Toxicities for Three Modern High-Dose Radiation Treatment Techniques for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 82:1, 204-212
CrossRef31
Lars Budäus, Michel Bolla, Alberto Bossi, Cesare Cozzarini, Juanita Crook, Anders Widmark, Thomas Wiegel. (2012) Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. European Urology 61:1, 112-127
CrossRef32
Vinod E. Nambudiri, Mary Beth Landrum, Elizabeth B. Lamont, Barbara J. McNeil, Samuel R. Bozeman, Stephen J. Freedland, Nancy L. Keating. (2012) Understanding Variation in Primary Prostate Cancer Treatment Within the Veterans Health Administration. Urology
CrossRef33
Lixin Song, Laurel L. Northouse, Lingling Zhang, Thomas M. Braun, Bernadine Cimprich, David L. Ronis, Darlene W. Mood. (2012) Study of dyadic communication in couples managing prostate cancer: a longitudinal perspective. Psycho-Oncology 21:1, 72-81
CrossRef34
Eric A. Klein. (2012) What is the best way to treat high-risk prostate cancer?. Cancer 118:1, 12-14
CrossRef35
Jatinder R. Palta, Jason A. Efstathiou, Justin E. Bekelman, Sasa Mutic, Carl R. Bogardus, Todd R. McNutt, Peter E. Gabriel, Colleen A. Lawton, Anthony L. Zietman, Christopher M. Rose. (2012) Developing a national radiation oncology registry: From acorns to oaks. Practical Radiation Oncology 2:1, 10-17
CrossRef36
Bradford S. Hoppe, Romaine C. Nichols, Randal H. Henderson, Christopher G. Morris, Christopher R. Williams, Joseph Costa, Robert B. Marcus, William M. Mendenhall, Zuofeng Li, Nancy P. Mendenhall. (2012) Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancern/a-n/a
CrossRef37
Jordan A. Holmes, Andrew Z. Wang, Karen E. Hoffman, Laura H. Hendrix, Julian G. Rosenman, William R. Carpenter, Paul A. Godley, Ronald C. Chen. (2012) Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study. International Journal of Radiation Oncology*Biology*Physics
CrossRef38
J. Taylor Whaley, Lawrence B. Levy, David A. Swanson, Thomas J. Pugh, Rajat J. Kudchadker, Teresa L. Bruno, Steven J. Frank. (2012) Sexual Function and the Use of Medical Devices or Drugs to Optimize Potency after Prostate Brachytherapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef39
Marisa A. Kollmeier, Michael J. Zelefsky. (2011) How to select the optimal therapy for early-stage prostate cancer. Critical Reviews in Oncology/Hematology
CrossRef40
Stephen A. Boorjian, James A. Eastham, Markus Graefen, Bertrand Guillonneau, R. Jeffrey Karnes, Judd W. Moul, Edward M. Schaeffer, Christian Stief, Kevin C. Zorn. (2011) A Critical Analysis of the Long-Term Impact of Radical Prostatectomy on Cancer Control and Function Outcomes. European Urology
CrossRef41
Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson, James M. McKiernan. (2011) Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Internationalno-no
CrossRef42
Katsuyoshi Hashine, Akihito Yuasa, Kensuke Shinomori, Iku Ninomiya, Masaaki Kataoka, Natsumi Yamashita. (2011) Health-related quality of life after radical retropubic prostatectomy and permanent prostate brachytherapy: A 3-year follow-up study. International Journal of Urology 18:12, 813-819
CrossRef43
H. Ballentine Carter. (2011) Management of low (favourable)-risk prostate cancer. BJU International 108:11, 1684-1695
CrossRef44
Alan Kaplan, Larissa German, Juza Chen, Haim Matzkin, Nicola J. Mabjeesh. (2011) Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with 125iodine brachytherapy. BJU Internationalno-no
CrossRef45
Julie L. Kasperzyk, William V. Shappley, Stacey A. Kenfield, Lorelei A. Mucci, Tobias Kurth, Jing Ma, Meir J. Stampfer, Martin G. Sanda. (2011) Watchful Waiting and Quality of Life Among Prostate Cancer Survivors in the Physicians' Health Study. The Journal of Urology 186:5, 1862-1867
CrossRef46
Ryan P. Smith, Heather A. Jones, Sushil Beriwal, Abhay Gokhale, Ronald Benoit. (2011) Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants. International Journal of Radiation Oncology*Biology*Physics 81:3, 745-750
CrossRef47
Eivind A.S. Steinsvik, Karol Axcrona, Alv A. Dahl, Lars M. Eri, Andreas Stensvold, Sophie D. Fosså. (2011) Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Internationalno-no
CrossRef48
Nicholas M. Pantelides, Sachin Agrawal, Chris Poullis, Andrew Chetwood, Mathias H. Winkler. (2011) Erectile dysfunction following radical prostatectomy: A review. British Journal of Medical and Surgical Urology 4:6, 227-242
CrossRef49
Jennifer E. Heckman, Karim Chamie, Sally L. Maliski, Arlene Fink, Lorna Kwan, Sarah E. Connor, Mark S. Litwin. (2011) The Role of Self-Efficacy in Quality of Life for Disadvantaged Men With Prostate Cancer. The Journal of Urology 186:5, 1855-1861
CrossRef50
R. Kirschner-Hermanns, T. Klementz, A. Haselhuhn, G. Jakse, A. Heidenreich, B. Brehmer. (2011) Drangsymptomatik nach onkologisch erfolgreicher Prostatakarzinomtherapie. Der Urologe 50:11, 1412-1419
CrossRef51
Harvey Quon, Patrick C.F. Cheung, D. Andrew Loblaw, Gerard Morton, Geordi Pang, Ewa Szumacher, Cyril Danjoux, Richard Choo, Alex Kiss, Alexandre Mamedov, Andrea Deabreu. (2011) Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef52
, Pascal Jean-Pierre, Kevin Fiscella, Paul C. Winters, Electra Paskett, Kristen Wells, Tracy Battaglia. (2011) Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. Supportive Care in Cancer
CrossRef53
Irving Kaplan, Elizabeth M. Genega, Neil Rofsky. 2011. Focal Therapy for Prostate Cancer Using Radiation. , 126-131.
CrossRef54
Cole Davis, Matthew Cooperberg, Peter R. Carroll. 2011. The Rationale for Focal Therapy of Prostate Cancer. , 1-10.
CrossRef55
Alexandra Masson-Lecomte, Vincent Hupertan, Eva Comperat, Christophe Vaessen, Emmanuel Chartier-Kastler, Olivier Cussenot, Marc-Olivier Bitker, Morgan Rouprêt. (2011) Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. World Journal of Urology 29:5, 665-670
CrossRef56
H. Ballentine Carter. (2011) Management of low (favourable)-risk prostate cancer. BJU Internationalno-no
CrossRef57
Natalia Sadetsky, Kirsten Greene, Matthew R. Cooperberg, Alan Hubbard, Peter R. Carroll, William Satariano. (2011) Impact of androgen deprivation on physical well-being in patients with prostate cancer. Cancer 117:19, 4406-4413
CrossRef58
Masaki Kimura, Lionel L. Bañez, Florian R. Schroeck, Leah Gerber, Jim Qi, Takefumi Satoh, Shiro Baba, Cary N. Robertson, Philip J. Walther, Craig F. Donatucci, Judd W. Moul, Thomas J. Polascik. (2011) Factors Predicting Early and Late Phase Decline of Sexual Health-Related Quality of Life Following Radical Prostatectomy. The Journal of Sexual Medicine 8:10, 2935-2943
CrossRef59
Carmen González-San Segundo, Felipe Herranz-Amo, Ana Álvarez-González, Pedro Cuesta-Álvaro, Marina Gómez-Espi, Eva Paños-Fagundo, Juan A. Santos-Miranda. (2011) Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Control—In Search of the Optimal Treatment. Annals of Surgical Oncology 18:10, 2980-2987
CrossRef60
Karim Chamie, Lorna Kwan, Sarah E. Connor, Mary Zavala, Jessica Labo, Mark S. Litwin. (2011) The impact of social networks and partnership status on treatment choice in men with localized prostate cancer. BJU Internationalno-no
CrossRef61
Martin Boettcher, Angelika Haselhuhn, Gerhard Jakse, Bernhard Brehmer, Ruth Kirschner-Hermanns. (2011) Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?. BJU Internationalno-no
CrossRef62
Steven C. Ames, Alex S. Parker, Julia E. Crook, Nancy N. Diehl, Winston W. Tan, Christopher R. Williams, Gretchen E. Ames. (2011) Quality of Life of Patients Undergoing Surgical Treatment for Newly-Diagnosed, Clinically Localized Renal Cell Carcinoma. Journal of Psychosocial Oncology 29:6, 593-605
CrossRef63
Michelle Cunich, Glenn Salkeld, Jack Dowie, Joan Henderson, Clare Bayram, Helena Britt, Kirsten Howard. (2011) Integrating Evidence and Individual Preferences Using a Web-Based Multi-Criteria Decision Analytic Tool. The Patient: Patient-Centered Outcomes Research 4:3, 153-162
CrossRef64
Eva Johansson, Gunnar Steineck, Lars Holmberg, Jan-Erik Johansson, Tommy Nyberg, Mirja Ruutu, Anna Bill-Axelson. (2011) Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. The Lancet Oncology 12:9, 891-899
CrossRef65
Allie N. Ivanowicz, Carolyn M. Wakeman, Ryan T. Hubbard, William B. DeVoe, Michael R. Haake, Chris M. Teigland. (2011) Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer. Brachytherapy
CrossRef66
J. Adam M. Cunha, Jean Pouliot, Vivian Weinberg, Alice Wang-Chesebro, Mack Roach, I-Chow Hsu. (2011) Urethra low-dose tunnels: Validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy
CrossRef67
Anthony V. D'Amico, Ming-Hui Chen, Daniel Dosoretz, Michael Katin, Sharon Salenius, Rudi Ross, Samuel Z. Goldhaber. (2011) Coronary Artery Revascularization and the Risk of Death in Men With Prostate Cancer. The Journal of Urology 186:3, 898-902
CrossRef68
Vipul R. Patel, Haidar M. Abdul-Muhsin, Oscar Schatloff, Rafael F. Coelho, Rair Valero, Young H. Ko, Ananthakrishnan Sivaraman, Kenneth J. Palmer, Sanket Chauhan. (2011) Critical review of ‘pentafecta’ outcomes after robot-assisted laparoscopic prostatectomy in high-volume centres. BJU International 108:6b, 1007-1017
CrossRef69
Peter Chang, Konrad M. Szymanski, Rodney L. Dunn, Jonathan J. Chipman, Mark S. Litwin, Paul L. Nguyen, Christopher J. Sweeney, Robert Cook, Andrew A. Wagner, William C. DeWolf, Glenn J. Bubley, Renee Funches, Joseph A. Aronovitz, John T. Wei, Martin G. Sanda. (2011) Expanded Prostate Cancer Index Composite for Clinical Practice: Development and Validation of a Practical Health Related Quality of Life Instrument for Use in the Routine Clinical Care of Patients With Prostate Cancer. The Journal of Urology 186:3, 865-872
CrossRef70
Jona A. Hattangadi, Ming-Hui Chen, Michelle H. Braccioforte, Brian J. Moran, Anthony V. D’Amico. (2011) Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy 10:5, 369-375
CrossRef71
Katherine Regan Sterba, Richard J. Swartz, Karen Basen-Engquist, Peter C. Black, Curtis A. Pettaway. (2011) Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. Supportive Care in Cancer 19:8, 1117-1124
CrossRef72
Piet Ost, Bart De Troyer, Valérie Fonteyne, Willem Oosterlinck, Gert De Meerleer. (2011) A Matched Control Analysis of Adjuvant and Salvage High-Dose Postoperative Intensity-Modulated Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 80:5, 1316-1322
CrossRef73
Masaki Kimura, Hui Yan, Zahid Rabbani, Takefumi Satoh, Shiro Baba, Fang-fang Yin, Thomas J. Polascik, Craig F. Donatucci, Zeljko Vujaskovic, Bridget F. Koontz. (2011) Radiation-Induced Erectile Dysfunction Using Prostate-Confined Modern Radiotherapy in a Rat Model. The Journal of Sexual Medicine 8:8, 2215-2226
CrossRef74
Daniela Wittmann, Chang He, Michael Coelho, Brent Hollenbeck, James E. Montie, David P. Wood. (2011) Patient Preoperative Expectations of Urinary, Bowel, Hormonal and Sexual Functioning Do Not Match Actual Outcomes 1 Year After Radical Prostatectomy. The Journal of Urology 186:2, 494-499
CrossRef75
David R. Yates, Morgan Rouprêt, Marc-Olivier Bitker, Christophe Vaessen. (2011) To Infinity and Beyond: The Robotic Toy Story. European Urology 60:2, 263-265
CrossRef76
Gerard C. Morton, D. Andrew Loblaw, Hans Chung, Gail Tsang, Raxa Sankreacha, Andrea Deabreu, Liying Zhang, Alexandre Mamedov, Patrick Cheung, Deidre Batchelar, Cyril Danjoux, Ewa Szumacher. (2011) Health-Related Quality of Life After Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 80:5, 1299-1305
CrossRef77
Mathieu Rouanne, Christophe Vaessen, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, Morgan Rouprêt. (2011) Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. Diseases of the Colon & Rectum 54:8, 1008-1013
CrossRef78
Frank Peinemann, Ulrich Grouven, Lars G Hemkens, Carmen Bartel, Holger Borchers, Michael Pinkawa, Axel Heidenreich, Stefan Sauerland, Frank Peinemann. 2011. Low-dose rate brachytherapy for men with localized prostate cancer. .
CrossRef79
Renuka Malik, Ashesh B. Jani, Stanley L. Liauw. (2011) External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS). International Journal of Radiation Oncology*Biology*Physics 80:4, 1080-1086
CrossRef80
Camille P. Vaughan, Patricia S. Goode, Kathryn L. Burgio, Alayne D. Markland. (2011) Urinary Incontinence in Older Adults. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:4, 558-570
CrossRef81
Véronique Beckendorf, Stéphane Guerif, Elisabeth Le Prisé, Jean-Marc Cosset, Agnes Bougnoux, Bruno Chauvet, Naji Salem, Olivier Chapet, Sylvain Bourdain, Jean-Marc Bachaud, Philippe Maingon, Jean-Michel Hannoun-Levi, Luc Malissard, Jean-Marc Simon, Pascal Pommier, Men Hay, Bernard Dubray, Jean-Léon Lagrange, Elisabeth Luporsi, Pierre Bey. (2011) 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics 80:4, 1056-1063
CrossRef82
Stephen A. Boorjian, R. Jeffrey Karnes, Rosalia Viterbo, Laureano J. Rangel, Eric J. Bergstralh, Eric M. Horwitz, Michael L. Blute, Mark K. Buyyounouski. (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117:13, 2883-2891
CrossRef83
Aaron D. Martin, Leah Y. Nakamura, Rafael N. Nunez, Christopher E. Wolter, Mitchell R. Humphreys, Erik P. Castle. (2011) Incontinence After Radical Prostatectomy: A Patient Centered Analysis and Implications for Preoperative Counseling. The Journal of Urology 186:1, 204-208
CrossRef84
Peter Rehder, George Webster. (2011) The AdVance® Male Sling: Patient Selection and Workup. European Urology Supplements 10:4, 390-394
CrossRef85
Cathryn Glazener, Charles Boachie, Brian Buckley, Claire Cochran, Grace Dorey, Adrian Grant, Suzanne Hagen, Mary Kilonzo, Alison McDonald, Gladys McPherson, Katherine Moore, John Norrie, Craig Ramsay, Luke Vale, James N'Dow. (2011) Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. The Lancet 378:9788, 328-337
CrossRef86
Shunichi Namiki, Yoichi Arai. (2011) Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men. Reproductive Medicine and Biology 10:2, 59-68
CrossRef87
Hua-yin Yu, William Ulmer, Keith J. Kowalczyk, Jim C. Hu. (2011) Health services research in urology. World Journal of Urology 29:3, 273-276
CrossRef88
Uri Lindner, Nathan Lawrentschuk, Oscar Schatloff, John Trachtenberg, Arie Lindner. (2011) Evolution from active surveillance to focal therapy in the management of prostate cancer. Future Oncology 7:6, 775-787
CrossRef89
Ricarda M. Bauer, Christian Gozzi, Wilhelm Hübner, Victor W. Nitti, Giacomo Novara, Andrew Peterson, Jaspreet S. Sandhu, Christian G. Stief. (2011) Contemporary Management of Postprostatectomy Incontinence. European Urology 59:6, 985-996
CrossRef90
Jim C. Hu, Hua-yin Yu, Keith J. Kowalczyk. (2011) Challenges of Interpreting and Improving Radical Prostatectomy Outcomes: Technique, Technology, Training, and Tactical Reporting. European Urology 59:6, 1073-1074
CrossRef91
Johnny Kao, Jamie A. Cesaretti, Nelson N. Stone, Richard G. Stock. (2011) Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity. Current Urology Reports 12:3, 237-242
CrossRef92
F. Gómez-Veiga. (2011) Comment to: “Results of 125-Iodine seed implant with preplanning system in 250 patients with prostate cancer”. Actas Urológicas Españolas (English Edition) 35:6, 345-346
CrossRef93
Carmel N. Anandadas, Noel W. Clarke, Susan E. Davidson, Patrick H. O’Reilly, John P. Logue, Lynne Gilmore, Ric Swindell, Richard J. Brough, Guy D. Wemyss-Holden, Maurice W. Lau, Pradip M. Javle, Vijay A.C. Ramani, James P. Wylie, Gerald N. Collins, Stephen Brown, Richard A. Cowan, . (2011) Early prostate cancer - which treatment do men prefer and why?. BJU International 107:11, 1762-1768
CrossRef94
Roman Ganzer, Jochen Neuhaus, Christian Gratzke, Andreas Blana, Wolf F. Wieland, Jens-Uwe Stolzenburg. (2011) Anatomical description of the periprostatic nerves in the male rhesus monkey (Macaca mulatta). World Journal of Urology 29:3, 375-380
CrossRef95
, Meredith Wallace Kazer, Janet Harden, Matthew Burke, Martin G. Sanda, Jill Hardy, Donald E. Bailey. (2011) The experiences of unpartnered men with prostate cancer: a qualitative analysis. Journal of Cancer Survivorship 5:2, 132-141
CrossRef96
J.-N. Cornu, T. Chanu, S. Beley, P. Sèbe, L. Peyrat, C. Ciofu, F. Haab. (2011) Chirurgie combinée par bandelette transobturatrice Advance et prothèse pénienne après prostatectomie totale : une première expérience. Progrès en Urologie 21:5, 349-353
CrossRef97
David Bowes, Juanita Crook. (2011) A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature. Current Opinion in Urology 21:3, 219-224
CrossRef98
Kenneth G. Nepple, Adam S. Kibel. (2011) Re: Active Surveillance Compared with Initial Treatment for Men with Low-Risk Prostate Cancer: A Decision Analysis. European Urology 59:5, 883-884
CrossRef99
Mei Lu, Svend O. Freytag, Hans Stricker, Jae Ho Kim, Kenneth Barton, Benjamin Movsas. (2011) Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemporary Clinical Trials 32:3, 453-460
CrossRef100
Abhishek Srivastava, Sonal Grover, Prasanna Sooriakumaran, Jaspreet Joneja, Ashutosh K Tewari. (2011) Robotic-assisted laparoscopic prostatectomy: a critical analysis of its impact on urinary continence. Current Opinion in Urology 21:3, 185-194
CrossRef101
Lars Budäus, Hartwig Huland, Markus Graefen. (2011) Controversies in the management of localized prostate cancer: Radical prostatectomy still the standard of care. Critical Reviews in Oncology/Hematology
CrossRef102
Michael Marberger. (2011) Is Robot-Assisted Radical Prostatectomy Safer Than Other Radical Prostatectomy Techniques?. European Urology 59:5, 699-700
CrossRef103
M. Nicole Lamb, Lucrecia Trabinino, Alan Hackford. (2011) Patientsʼ Perspectives on Fecal Incontinence After Brachytherapy for Localized Prostate Cancer. Diseases of the Colon & Rectum 54:5, 615-621
CrossRef104
Bilal Chughtai, Jaspreet S. Sandhu. (2011) Incontinence: Conservative treatment of postprostatectomy incontinence. Nature Reviews Urology 8:5, 237-238
CrossRef105
Jonathan D. Grant, Mark S. Litwin, Lorna Kwan, Steve P. Lee, Michael L. Steinberg, Christopher R. King. (2011) Does Hormone Therapy Exacerbate the Adverse Effects of Radiotherapy in Men With Prostate Cancer? A Quality of Life Study. The Journal of Urology 185:5, 1674-1680
CrossRef106
Jesse Sammon, Quoc-Dien Trinh, Mani Menon. (2011) Robotic radical prostatectomy: a critical analysis of surgical quality. Current Opinion in Urology 21:3, 195-199
CrossRef107
Nathan Lawrentschuk, Laurence Klotz. (2011) Active surveillance for low-risk prostate cancer: an update. Nature Reviews Urology 8:6, 312-320
CrossRef108
Laercio A Silva, Régis B Andriolo, Álvaro N Atallah, Edina MK da Silva, Laercio A Silva. 2011. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. .
CrossRef109
Peter L. Steinberg, Reza Ghavamian. (2011) Searching Robotic Prostatectomy Online: What Information Is Available?. Urology 77:4, 941-945
CrossRef110
K. Steenland, M. Goodman, J. Liff, C. DiIorio, S. Butler, P. Roberts. (2011) Quality of Life Among Men With Prostate Cancer in Rural Georgia. Urology 77:4, 927-933
CrossRef111
Emilie K. Johnson, Ryan C. Hedgepeth, Chang He, David P. Wood. (2011) The Impact of Anterior Urethropexy During Robotic Prostatectomy on Urinary and Sexual Outcomes. Journal of Endourology 25:4, 615-619
CrossRef112
Douglas E. Sutherland, Brian Linder, Anna M. Guzman, Mark Hong, Harold A. Frazier, Jason D. Engel, Fernando J. Bianco. (2011) Posterior Rhabdosphincter Reconstruction During Robotic Assisted Radical Prostatectomy: Results From a Phase II Randomized Clinical Trial. The Journal of Urology 185:4, 1262-1267
CrossRef113
W. Robert Lee. (2011) Editorial Comment. Urology 77:4, 991
CrossRef114
Alberto Briganti, Andrea Gallina, Nazareno Suardi, Umberto Capitanio, Manuela Tutolo, Marco Bianchi, Andrea Salonia, Renzo Colombo, Valerio Di Girolamo, Juan Ignazio Martinez-Salamanca, Giorgio Guazzoni, Patrizio Rigatti, Francesco Montorsi. (2011) What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. The Journal of Sexual Medicine 8:4, 1210-1217
CrossRef115
Steven C. Ames, Winston W. Tan, Gretchen E. Ames, Ronald L. Stone, Thomas D. Rizzo, Julia E. Crook, Christopher R. Williams, Chudley E. Werch, Matthew M. Clark, Teresa A. Rummans. (2011) A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psycho-Oncology 20:4, 435-440
CrossRef116
Sharon L. Manne, David W. Kissane, Christian J. Nelson, John P. Mulhall, Gary Winkel, Talia Zaider. (2011) Intimacy-Enhancing Psychological Intervention for Men Diagnosed with Prostate Cancer and Their Partners: A Pilot Study. The Journal of Sexual Medicine 8:4, 1197-1209
CrossRef117
Cole Davis, Matthew R. Cooperberg, Katsuto Shinohara, Peter R. Carroll. 2011. Rationale for Minimally Invasive Interventional Techniques in Urological Cancer. , 1-9.
CrossRef118
N. Kamo, S. V. Dandapani, R. A. Miksad, M. J. Houlihan, I. Kaplan, M. Regan, T. K. Greenfield, M. G. Sanda. (2011) Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. Annals of Oncology 22:3, 723-729
CrossRef119
Scott E. Eggener, Peter T. Scardino, Patrick C. Walsh, Misop Han, Alan W. Partin, Bruce J. Trock, Zhaoyong Feng, David P. Wood, James A. Eastham, Ofer Yossepowitch, Danny M. Rabah, Michael W. Kattan, Changhong Yu, Eric A. Klein, Andrew J. Stephenson. (2011) Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. The Journal of Urology 185:3, 869-875
CrossRef120
Kyle Steenland, Michael Goodman, Jonathan Liff, Colleen Diiorio, Susan Butler, Phil Roberts, Judith L. Smith, Donatus Ekwueme, Ingrid J. Hall. (2011) The Effect of Race and Rural Residence on Prostate Cancer Treatment Choice Among Men in Georgia. Urology 77:3, 581-587
CrossRef121
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Kaufman, Donald S., Zietman, Anthony L., Dahl, Douglas M., Harisinghani, Mukesh G., Wu, Chin-Lee, . (2011) Case 5-2011. New England Journal of Medicine 364:7, 667-675
Full Text122
Pascal Jean-Pierre, Kevin Fiscella, Karen M. Freund, Jack Clark, Julie Darnell, Alan Holden, Douglas Post, Steven R. Patierno, Paul C. Winters, . (2011) Structural and reliability analysis of a patient satisfaction with cancer-related care measure. Cancer 117:4, 854-861
CrossRef123
Walter R. Parker, Rou Wang, Chang He, David P. Wood Jr. (2011) Five year Expanded Prostate cancer Index Composite-based quality of life outcomes after prostatectomy for localized prostate cancer. BJU International 107:4, 585-590
CrossRef124
Wesley W. Choi, Marcos P. Freire, Jane R. Soukup, Lei Yin, Stuart R. Lipsitz, Fernando Carvas, Stephen B. Williams, Jim C. Hu. (2011) Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. World Journal of Urology 29:1, 21-27
CrossRef125
Adam W. Levinson, Hugh J. Lavery, Nicholas T. Ward, Li-Ming Su, Christian P. Pavlovich. (2011) Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy. World Journal of Urology 29:1, 29-34
CrossRef126
Bruce L. Jacobs, Erin P. Gibbons, Ryan P. Smith, Sushil Beriwal, Ronald M. Benoit. (2011) Acute bowel morbidity after prostate brachytherapy with cesium-131. Brachytherapy 10:1, 51-56
CrossRef127
Lindsey Reichlin, Nithya Mani, Kara McArthur, Amy M Harris, Nithin Rajan, Clifford C Dacso. (2011) Assessing the Acceptability and Usability of an Interactive Serious Game in Aiding Treatment Decisions for Patients with Localized Prostate Cancer. Journal of Medical Internet Research 13:1,
CrossRef128
Tom Pickles, W. James Morris, Michael W. Kattan, Changhong Yu, Mira Keyes. (2011) Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy 10:1, 9-14
CrossRef129
Amitabh Chandra, David Cutler, Zirui Song. 2011. Who Ordered That? The Economics of Treatment Choices in Medical Care. , 397-432.
CrossRef130
Andreas Stensvold, Alv A. Dahl, Bjørn Brennhovd, Milada Cvancarova, Sophie D. Fosså, Wolfgang Lilleby, Karol Axcrona, Sigbjørn Smeland. (2011) Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. The Prostaten/a-n/a
CrossRef131
Stephen B. Williams, Simpa Salami, Meredith M. Regan, Donna P. Ankerst, John T. Wei, Mark A. Rubin, Ian M. Thompson, Martin G. Sanda. (2011) Selective detection of histologically aggressive prostate cancer. Cancern/a-n/a
CrossRef132
Luigi Mearini, Massimo Porena. (2011) Pros and Cons of Focal Therapy for Localised Prostate Cancer. Prostate Cancer 2011, 1-8
CrossRef133
Sae Woong Kim. (2011) Prostatic Disease and Sexual Dysfunction. Korean Journal of Urology 52:6, 373
CrossRef134
Firas Abdollah, Maxine Sun, Rodolphe Thuret, Claudio Jeldres, Zhe Tian, Alberto Briganti, Shahrokh F. Shariat, Paul Perrotte, Patrizio Rigatti, Francesco Montorsi, Pierre I. Karakiewicz. (2011) A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006. European Urology 59:1, 88-95
CrossRef135
Eric K Oermann, Simeng Suy, Heather N Hanscom, Joy S Kim, Sue Lei, Xia Yu, Guowei Zhang, Brook Ennis, JoyAnn P Rohan, Nathaniel Piel, Benjamin A Sherer, Devin Borum, Viola J Chen, Gerald P Batipps, Nicholas L Constantinople, Stephen W Dejter, Gaurav Bandi, John Pahira, Kevin G McGeagh, Lucile Adams-Campbell, Reena Jha, Nancy A Dawson, Brian T Collins, Anatoly Dritschilo, John H Lynch, Sean P Collins. (2011) Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. Journal of Hematology & Oncology 4:1, 12
CrossRef136
Jean-Nicolas Cornu, Benoit Merlet, Calin Ciofu, Stéphane Mouly, Laurence Peyrat, Philippe Sèbe, René Yiou, Guy Vallancien, Isabelle Debrix, Karim Laribi, Olivier Cussenot, François Haab. (2011) Duloxetine for Mild to Moderate Postprostatectomy Incontinence: Preliminary Results of a Randomised, Placebo-Controlled Trial. European Urology 59:1, 148-154
CrossRef137
Michael Pinkawa, Richard Holy, Marc D. Piroth, Jens Klotz, David Pfister, Axel Heidenreich, Michael J. Eble. (2011) Interpreting the Clinical Significance of Quality of Life Score Changes after Radiotherapy for Localized Prostate Cancer. Current Urology 5:3, 137-144
CrossRef138
Pierre J. Mendoza, Joshua M. Stern, Amy Y. Li, William Jaffe, Robert Kovell, Mary Nguyen, Rachel Natale, Kelly Monahan, Meredith R. Bergey, David I. Lee. (2011) Pelvic Anatomy on Preoperative Magnetic Resonance Imaging Can Predict Early Continence After Robot-Assisted Radical Prostatectomy. Journal of Endourology 25:1, 51-55
CrossRef139
Steven J. Frank, Lawrence B. Levy, Marco van Vulpen, Juanita Crook, John Sylvester, Peter Grimm, Thomas J. Pugh, David A. Swanson. (2011) Outcomes after prostate brachytherapy are even better than predicted. Cancern/a-n/a
CrossRef140
U. Lindner, N. Lawrentschuk, J. Trachtenberg. (2010) Image guidance for focal therapy of prostate cancer. World Journal of Urology 28:6, 727-734
CrossRef141
Gautam Jayram, Mark H. Katz, Gary D. Steinberg. (2010) Radical Cystectomy in Patients Previously Treated for Localized Prostate Cancer. Urology 76:6, 1430-1433
CrossRef142
Kathryn L. Taylor, Kimberly M. Davis, Tara Lamond, Randi M. Williams, Marc D. Schwartz, William Lawrence, Shibao Feng, Susan Brink, Amy Birney, John Lynch, James Regan, Anatoly Dritschilo. (2010) Use and Evaluation of a CD-ROM-Based Decision Aid for Prostate Cancer Treatment Decisions. Behavioral Medicine 36:4, 130-140
CrossRef143
Christopher F. Sharpley, David R. H. Christie, Vicki Bitsika. (2010) Variability in Anxiety and Depression Over Time Following Diagnosis in Patients with Prostate Cancer. Journal of Psychosocial Oncology 28:6, 644-665
CrossRef144
Eva Compérat, Morgan Rouprêt, Sarah J. Drouin, Philippe Camparo, Marc-Olivier Bitker, Alain Houlgatte, Géraldine Cancel-Tassin, Olivier Cussenot. (2010) Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. The Prostate 70:15, 1622-1627
CrossRef145
James Higham-Kessler, Ira J. Kodner, Jason D. Keune. (2010) Ethical counseling of an indecisive patient with low-risk prostate carcinoma: A case study. Surgery 148:5, 1022-1025
CrossRef146
Anurag K. Singh, Terry L. Mashtare, Susan A. McCloskey, Stefanie A. Seixas-Mikelus, Hyung L. Kim, Kilian Salerno May. (2010) Increasing Age and Treatment Modality Are Predictors for Subsequent Diagnosis of Bladder Cancer Following Prostate Cancer Diagnosis. International Journal of Radiation Oncology*Biology*Physics 78:4, 1086-1094
CrossRef147
Konrad M. Szymanski, John T. Wei, Rodney L. Dunn, Martin G. Sanda. (2010) Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors. Urology 76:5, 1245-1250
CrossRef148
Paul L. Nguyen, Ronald C. Chen, Karen E. Hoffman, Alexei Trofimov, Jason A. Efstathiou, John J. Coen, William U. Shipley, Anthony L. Zietman, James A. Talcott. (2010) Rectal Dose–Volume Histogram Parameters Are Associated With Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. International Journal of Radiation Oncology*Biology*Physics 78:4, 1081-1085
CrossRef149
Geetu Pahlajani, Rupesh Raina, J. Stephen Jones, Michael Burdick, Marwan Ali, Jianbo Li, Arul Mahadevan, Jay Ciezki, Craig Zippe. (2010) Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU International 106:10, 1524-1527
CrossRef150
Judith Evers, Nina Kupper, Dionne Kessing, Rob Davits, Antoine Engelen, Philip Poortmans, Floortje Mols. (2010) No Long-term Effects of Hormonal Therapy Preceding Brachytherapy on Urinary Function and Health-related Quality of Life Among Prostate Cancer Patients. Urology 76:5, 1150-1156
CrossRef151
Nitya E. Abraham, Danil V. Makarov, Juliana Laze, Elina Stefanovics, Rani Desai, Herbert Lepor. (2010) Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy. The Journal of Urology 184:5, 1977-1981
CrossRef152
Uri Lindner, John Trachtenberg, Nathan Lawrentschuk. (2010) Focal therapy in prostate cancer: modalities, findings and future considerations. Nature Reviews Urology 7:10, 562-571
CrossRef153
Abhay S. Gokhale, Sushil Beriwal, Ryan P. Smith, Xiang Li, Ronald Benoit. (2010) Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with 131Cs brachytherapy for prostate cancer. Brachytherapy 9:4, 328-334
CrossRef154
Anna Wilkins, Chris Parker. (2010) Treating prostate cancer with radiotherapy. Nature Reviews Clinical Oncology 7:10, 583-589
CrossRef155
Ellen A. Wiegner, Christopher R. King. (2010) Sexual Function After Stereotactic Body Radiotherapy for Prostate Cancer: Results of a Prospective Clinical Trial. International Journal of Radiation Oncology*Biology*Physics 78:2, 442-448
CrossRef156
Steven B Zeliadt, Scott D Ramsey. (2010) Cost–effectiveness of prostate cancer chemoprevention among high-risk men. Expert Review of Pharmacoeconomics & Outcomes Research 10:5, 505-508
CrossRef157
William M. Mendenhall, R. Charles Nichols, Randal Henderson, Nancy P. Mendenhall. (2010) Is Radical Prostatectomy the “Gold Standard” for Localized Prostate Cancer?. American Journal of Clinical Oncology 33:5, 511-515
CrossRef158
Sarah J. Drouin, Eva Comperat, Olivier Cussenot, Marc-Olivier Bitker, Alain Haertig, Morgan Rouprêt. (2010) Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. Urologic Oncology: Seminars and Original Investigations
CrossRef159
John L. Gore, Kiran Gollapudi, Jonathan Bergman, Lorna Kwan, Tracey L. Krupski, Mark S. Litwin. (2010) Correlates of Bother Following Treatment for Clinically Localized Prostate Cancer. The Journal of Urology 184:4, 1309-1315
CrossRef160
Nobumichi Tanaka, Kiyohide Fujimoto, Isao Asakawa, Akihide Hirayama, Tatsuo Yoneda, Katsunori Yoshida, Yoshihiko Hirao, Masatoshi Hasegawa, Noboru Konishi. (2010) Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer. Brachytherapy 9:4, 300-306
CrossRef161
Anne E. Kyrdalen, Alv A. Dahl, Eivor Hernes, Einar Hem, Sophie D. Fosså. (2010) Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. The Prostate 70:13, 1480-1489
CrossRef162
Oliver Sartor. (2010) Prostate cancer: Saturation biopsy does not accurately localize tumors. Nature Reviews Urology 7:9, 479-480
CrossRef163
Phillip M. Pierorazio, Elizabeth Humphreys, Patrick C. Walsh, Alan W. Partin, Misop Han. (2010) Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU International 106:6, 791-795
CrossRef164
Stacy Elliott, David M. Latini, Lauren M. Walker, Richard Wassersug, John W. Robinson, . (2010) Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life. The Journal of Sexual Medicine 7:9, 2996-3010
CrossRef165
P J van Leeuwen, H A van Vugt, C H Bangma. (2010) The implementation of screening for prostate cancer. Prostate Cancer and Prostatic Diseases 13:3, 218-227
CrossRef166
John T. Wei. (2010) Limitations of a contemporary prostate biopsy: The blind march forward. Urologic Oncology: Seminars and Original Investigations 28:5, 546-549
CrossRef167
Angelish Kumar, Victor W. Nitti. (2010) Contemporary Incidence of Postprostatectomy Incontinence and Impact on Health-related Quality of Life. Current Bladder Dysfunction Reports 5:3, 135-141
CrossRef168
Sunao Shoji, Mayura Nakano, Yoshihiro Nagata, Yukio Usui, Toshiro Terachi, Toyoaki Uchida. (2010) Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: A prospective study. International Journal of Urology 17:8, 715-719
CrossRef169
Vasundara Venkateswaran, Laurence H. Klotz. (2010) Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nature Reviews Urology 7:8, 442-453
CrossRef170
Jean-Nicolas Cornu, Véronique Phé, Georges Fournier, Vincent Delmas, Philippe Sèbe. (2010) Fascia surrounding the prostate: clinical and anatomical basis of the nerve-sparing radical prostatectomy. Surgical and Radiologic Anatomy 32:7, 663-667
CrossRef171
E. Andreas Svaboe Steinsvik, Sophie D. Fosså, Karol Axcrona, Per Fransson, Anders Widmark, Alv A. Dahl. (2010) Do Perceptions of Adverse Events Differ Between Patients and Physicians? Findings From a Randomized, Controlled Trial of Radical Treatment for Prostate Cancer. The Journal of Urology 184:2, 525-531
CrossRef172
Ryan J. Burri, Nelson N. Stone, Pam Unger, Richard G. Stock. (2010) Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 77:5, 1338-1344
CrossRef173
Peter C. Albertsen. (2010) Treatment of localized prostate cancer: when is active surveillance appropriate?. Nature Reviews Clinical Oncology 7:7, 394-400
CrossRef174
Karen M. Winkfield, Michelle A. Albert. (2010) Unanswered Questions Regarding the Effect of Androgen Deprivation Therapy for Prostate Cancer on Cardiovascular Disease Risk in Black Men. Current Cardiovascular Risk Reports 4:4, 311-317
CrossRef175
Virginie Marchand, Sylvain Bourdin, Christelle Charbonnel, Emmanuel Rio, Camille Munos, Loïc Campion, Angélique Bonnaud-Antignac, Albert Lisbona, Marc-André Mahé, Stéphane Supiot. (2010) No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study. International Journal of Radiation Oncology*Biology*Physics 77:4, 1053-1059
CrossRef176
Alex Shteynshlyuger, Adam S. Kibel. (2010) Counterpoint: Prostate carcinoma treatment for the young patient—The case for radical prostatectomy. Brachytherapy 9:3, 195-198
CrossRef177
Isabel Syndikus, Rachel C. Morgan, Matthew R. Sydes, John D. Graham, David P. Dearnaley. (2010) Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397). International Journal of Radiation Oncology*Biology*Physics 77:3, 773-783
CrossRef178
Kent E. Wallner. (2010) Point: Prostate carcinoma treatment for the young patient—The case for brachytherapy. Brachytherapy 9:3, 193-194
CrossRef179
Scott D. Ramsey, Steven B. Zeliadt, Neeraj K. Arora, David K. Blough, David F. Penson, Ingrid Oakley-Girvan, Ann S. Hamilton, Stephen K. Van Den Eeden, Catherine R. Fedorenko, Arnold L. Potosky. (2010) Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. The Journal of Urology 184:1, 120-125
CrossRef180
Uri Lindner, Nathan Lawrentschuk, Robert A. Weersink, Orit Raz, Eugen Hlasny, Marshall S. Sussman, Sean R. Davidson, Mark R. Gertner, John Trachtenberg. (2010) Construction and Evaluation of an Anatomically Correct Multi-Image Modality Compatible Phantom for Prostate Cancer Focal Ablation. The Journal of Urology 184:1, 352-357
CrossRef181
Heidi A van Vugt, Chris H Bangma, Monique J Roobol. (2010) Should prostate-specific antigen screening be offered to asymptomatic men?. Expert Review of Anticancer Therapy 10:7, 1043-1053
CrossRef182
Jonathan Bergman, Lorna Kwan, Mark S. Litwin. (2010) Improving Decisions for Men With Prostate Cancer: Translational Outcomes Research. The Journal of Urology 183:6, 2186-2192
CrossRef183
W. Robert Lee. (2010) Editorial Comment. Urology 75:6, 1416-1417
CrossRef184
Andrew R. McCullough, Wayne G. Hellstrom, Run Wang, Herbert Lepor, Kristofer R. Wagner, Jason D. Engel. (2010) Recovery of Erectile Function After Nerve Sparing Radical Prostatectomy and Penile Rehabilitation With Nightly Intraurethral Alprostadil Versus Sildenafil Citrate. The Journal of Urology 183:6, 2451-2456
CrossRef185
Jennifer M. Croswell, David F. Ransohoff, Barnett S. Kramer. (2010) Principles of Cancer Screening: Lessons From History and Study Design Issues. Seminars in Oncology 37:3, 202-215
CrossRef186
Ravishankar Jayadevappa, J Sanford Schwartz, Sumedha Chhatre, Alan J. Wein, S. Bruce Malkowicz. (2010) Association between utility and treatment among patients with prostate cancer. Quality of Life Research 19:5, 711-720
CrossRef187
Alberto Briganti, Andrea Gallina, Nazareno Suardi, Umberto Capitanio, Manuela Tutolo, Marco Bianchi, Niccolò Passoni, Andrea Salonia, Renzo Colombo, Valerio Di Girolamo, Giorgio Guazzoni, Patrizio Rigatti, Francesco Montorsi. (2010) Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. Journal of Sexual Medicineno-no
CrossRef188
Murray Krahn. (2010) ‘New’ Evidence for Clinical Practice Guidelines. The Patient: Patient-Centered Outcomes Research 3:2, 71-77
CrossRef189
George J. Huang, Natalia Sadetsky, David F. Penson. (2010) Health Related Quality of Life for Men Treated for Localized Prostate Cancer With Long-Term Followup. The Journal of Urology 183:6, 2206-2212
CrossRef190
A. Horwich, C. Parker, C. Bangma, V. Kataja, . (2010) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v129-v133
CrossRef191
John B. Malcolm, Michael D. Fabrizio, Bethany B. Barone, Robert W. Given, Raymond S. Lance, Donald F. Lynch, John W. Davis, Mark E. Shaves, Paul F. Schellhammer. (2010) Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer. The Journal of Urology 183:5, 1822-1829
CrossRef192
Howard M. Sandler, Ping-Yu Liu, Rodney L. Dunn, David C. Khan, Scott E. Tropper, Martin G. Sanda, Constantine A. Mantz. (2010) Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study. Urology 75:5, 1004-1008
CrossRef193
Jonathan Bergman, John L. Gore, Jennifer S. Singer, Jennifer T. Anger, Mark S. Litwin. (2010) Readability of Health Related Quality of Life Instruments in Urology. The Journal of Urology 183:5, 1977-1981
CrossRef194
Karen E. Hoffman, Paul L. Nguyen, Andrea K. Ng, Anthony V. D'Amico. (2010) Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy. The Journal of Urology 183:5, 1798-1802
CrossRef195
J. de la Rosette, H. Ahmed, J. Barentsz, T. Bjerklund Johansen, M. Brausi, M. Emberton, F. Frauscher, D. Greene, M. Harisinghani, K. Haustermans, A. Heidenreich, G. Kovacs, M. Mason, R. Montironi, V. Mouraviev, T. de Reijke, S. Taneja, S. Thuroff, B. Tombal, J. Trachtenberg, H. Wijkstra, T. Polascik. (2010) Focal Therapy in Prostate Cancer—Report from a Consensus Panel. Journal of Endourology 24:5, 775-780
CrossRef196
, , , Ferran Guedea, Alfredo Ramos, Ismael Herruzo, José Antonio Sánchez Calzado, Jorge Contreras, Jesús Romero, Jordi Craven-Bartle, Patricia Willisch, José Luis López Torrecilla, Xavier Maldonado, Gemma Sancho, Almudena Zapatero, Montserrat Ferrer, Yolanda Pardo, Pablo Fernández, Alfonso Mariño, Asunción Hervás, Víctor Macías, Ana Boladeras, Ferran Ferrer, Brian J. Davis. (2010) Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. Clinical and Translational Oncology 12:5, 315-317
CrossRef197
Uri Lindner, Nathan Lawrentschuk, John Trachtenberg. (2010) Focal Laser Ablation for Localized Prostate Cancer. Journal of Endourology 24:5, 791-797
CrossRef198
Y. C. Tsai, C. C. Hung, S. J. Hwang, S. L. Wang, S. M. Hsiao, M. Y. Lin, L. F. Kung, P. N. Hsiao, H. C. Chen. (2010) Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease. Nephrology Dialysis Transplantation 25:5, 1621-1626
CrossRef199
Roderick C.N. van den Bergh, Hanna Vasarainen, Henk G. van der Poel, Jenneke J. Vis-Maters, John B. Rietbergen, Tom Pickles, Erik B. Cornel, Riccardo Valdagni, Joris J. Jaspars, John van der Hoeven, Frederic Staerman, Eric H.G.M. Oomens, Antti Rannikko, Stijn Roemeling, Ewout W. Steyerberg, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma. (2010) Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU International 105:7, 956-962
CrossRef200
Arthur K. Cheung, Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Daniel E. Dosoretz, Sharon Salenius, Michael Katin, Rudi Ross, Anthony V. D'Amico. (2010) The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy 9:2, 145-150
CrossRef201
Evanguelos Xylinas, Guillaume Ploussard, Laurent Salomon, Alexandre Paul, Norman Gillion, Kevin De Laet, Dimitri Vordos, Andras Hoznek, Clément-Claude Abbou, Alexandre de la Taille. (2010) Intrafascial Nerve-Sparing Radical Prostatectomy with a Laparoscopic Robot-Assisted Extraperitoneal Approach: Early Oncological and Functional Results. Journal of Endourology 24:4, 577-582
CrossRef202
Christian Boukaram, Jean-Michel Hannoun-Levi. (2010) Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treatment Reviews 36:2, 91-100
CrossRef203
Akash Nanda, Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Daniel Dosoretz, Sharon Salenius, Michael Katin, Rudi Ross, Anthony V. D'Amico. (2010) Total Androgen Blockade Versus a Luteinizing Hormone–Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 76:5, 1439-1444
CrossRef204
Michaella M. Prasad, Sandip M. Prasad, Nathanael D. Hevelone, Xiangmei Gu, Aaron C. Weinberg, Stuart R. Lipsitz, Ganesh S. Palapattu, Jim C. Hu. (2010) Utilization of Pharmacotherapy for Erectile Dysfunction Following Treatment for Prostate Cancer. Journal of Sexual Medicine 7:3, 1062-1073
CrossRef205
V Tombolini, M Di Staso, P Bonfili, M Di Genesio Pagliuca, P Franzese, S Buonopane, M Valeriani, R Maurizi Enrici, C Festuccia, G L Gravina. (2010) Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer. Prostate Cancer and Prostatic Diseases 13:1, 34-38
CrossRef206
J. Kellogg Parsons, Lorna Kwan, Sarah E. Connor, David C. Miller, Mark S. Litwin. (2010) Prostate cancer treatment for economically disadvantaged men. Cancer 116:5, 1378-1384
CrossRef207
Kevin R. Loughlin, Michaella M. Prasad. (2010) Post-Prostatectomy Urinary Incontinence: A Confluence of 3 Factors. The Journal of Urology 183:3, 871-877
CrossRef208
Mack Roach, Jiho Nam, Giovanna Gagliardi, Issam El Naqa, Joseph O. Deasy, Lawrence B. Marks. (2010) Radiation Dose–Volume Effects and the Penile Bulb. International Journal of Radiation Oncology*Biology*Physics 76:3, S130-S134
CrossRef209
Roderick C. N. van den Bergh, Ewout W. Steyerberg, Ali Khatami, Gunnar Aus, Carl Gustaf Pihl, Tineke Wolters, Pim J. van Leeuwen, Monique J. Roobol, Fritz H. Schröder, Jonas Hugosson, . (2010) Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?. Cancer 116:5, 1281-1290
CrossRef210
E. David Crawford, Gerald L. Andriole, Michael Marberger, Roger S. Rittmaster. (2010) Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial. Urology 75:3, 502-509
CrossRef211
Kathleen Y. Wolin, Jason Luly, Siobhan Sutcliffe, Gerald L. Andriole, Adam S. Kibel. (2010) Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and Obesity. The Journal of Urology 183:2, 629-633
CrossRef212
Alex Shteynshlyuger, Gerald L. Andriole. (2010) Prostate Cancer: To Screen or Not to Screen?. Urologic Clinics of North America 37:1, 1-9
CrossRef213
Mark H. Eckman, Jun Ying, Kara Hertzfeld, Nitin Kumar, William Barrett. (2010) Longitudinal Analysis of Genitourinary and Bowel Symptoms in Prostate Cancer Patients Following Brachytherapy. American Journal of Clinical Oncology 33:1, 1-10
CrossRef214
Andrew J. Stephenson, Robert Abouassaly, Eric A. Klein. (2010) Chemoprevention of Prostate Cancer. Urologic Clinics of North America 37:1, 11-21
CrossRef215
C. Shad Thaxton, Stacy Loeb, Kimberly A. Roehl, Donghui Kan, William J. Catalona. (2010) Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Protocols. Urology 75:2, 414-418
CrossRef216
Darren Katz, Nelson E. Bennett, Jason Stasi, James A. Eastham, Bertrand D. Guillonneau, Peter T. Scardino, John P. Mulhall. (2010) Chronology of Erectile Function in Patients with Early Functional Erections Following Radical Prostatectomy. Journal of Sexual Medicine 7:2pt1, 803-809
CrossRef217
Hashim U Ahmed, Mark Emberton. (2010) Is focal therapy the future for prostate cancer?. Future Oncology 6:2, 261-268
CrossRef218
Laercio A Silva, Régis B Andriolo, Álvaro N Atallah, Edina MK da Silva, Laercio A Silva. 2010. Surgery for urinary incontinence due to presumed sphincter deficiency after prostate surgery. .
CrossRef219
Nathan Lawrentschuk, Laurence Klotz. (2010) Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review. Korean Journal of Urology 51:10, 665
CrossRef220
Philip Vigneri, Amin S. Herati, Louis Potters. (2010) The second decade of prostate brachytherapy: Evidence and cost based outcomes. Urologic Oncology: Seminars and Original Investigations 28:1, 86-90
CrossRef221
Joshua Siglin, Gregory J. Kubicek, Benjamin Leiby, Richard K. Valicenti. (2010) Time of Decline in Sexual Function After External Beam Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 76:1, 31-35
CrossRef222
Svetomir Dragićević, Tamara Naumović, Ivan Soldatović, Sava Mićić, Cane Tulić, Tatjana Pekmezović. (2010) Evaluation of Health-Related Quality of Life in Patients with Prostate Cancer after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy. Urologia Internationalis 85:2, 173-179
CrossRef223
Heather S. L. Jim, Brent J. Small, Stephen Patterson, Raoul Salup, Paul B. Jacobsen. (2010) Cognitive impairment in men treated with luteinizing hormone–releasing hormone agonists for prostate cancer: a controlled comparison. Supportive Care in Cancer 18:1, 21-27
CrossRef224
X. Maldonado, G. Sancho, M. Ferrer, F. Guedea. (2010) Critical review of the use of radiotherapy as initial treatment of localized prostate cancer. Actas Urológicas Españolas (English Edition) 34:5, 401-402
CrossRef225
Steven E. Canfield, Philipp Dahm, . (2010) Evidence-based urology in practice: incorporating patient values in evidence-based clinical decision making. BJU International 105:1, 4-5
CrossRef226
S Eggener, M Gonzalgo, O Yossepowitch. (2009) Regarding: ‘High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series’. British Journal of Cancer 101:12, 2057-2058
CrossRef227
Scott Ely. (2009) Personalized medicine: individualized care of cancer patients. Translational Research 154:6, 303-308
CrossRef228
William W. Wong, Sujay A. Vora, Steven E. Schild, Gary A. Ezzell, Paul E. Andrews, Robert G. Ferrigni, Scott K. Swanson. (2009) Radiation dose escalation for localized prostate cancer. Cancer 115:23, 5596-5606
CrossRef229
Gregory P. Beehler, Michael Wade, Borah Kim, Lynn Steinbrenner, Laura O. Wray. (2009) Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors. Journal of Cancer Survivorship 3:4, 233-240
CrossRef230
Jean-Nicolas Cornu, Francois Haab. (2009) Reply from Authors re: Drogo K. Montague. Males Slings: Compressive versus Repositioning. Eur Urol 2009;56:934–5. European Urology 56:6, 936
CrossRef231
Jeffery C. Wheat, Ryan C. Hedgepeth, Chang He, LingLing Zhang, David P. Wood. (2009) Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary Score. The Journal of Urology 182:6, 2844-2849
CrossRef232
L Fairley, M Baker, J Whiteway, W Cross, D Forman. (2009) Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006. British Journal of Cancer 101:11, 1839-1845
CrossRef233
Claudio Fiorino, Riccardo Valdagni, Tiziana Rancati, Giuseppe Sanguineti. (2009) Dose–volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology 93:2, 153-167
CrossRef234
Ajay Sandhu, Arno J. Mundt. (2009) Radiation therapy for urologic malignancies in the elderly. Urologic Oncology: Seminars and Original Investigations 27:6, 643-652
CrossRef235
Geoffrey A. Sonn, Natalia Sadetsky, Joseph C. Presti, Mark S. Litwin. (2009) Differing Perceptions of Quality of Life in Patients With Prostate Cancer and Their Doctors. The Journal of Urology 182:5, 2296-2302
CrossRef236
Peter Branney, Alan White, Sunjay Jain, Chris Hiley, Paul Flowers. (2009) Choosing Health, Choosing Treatment: Patient Choice After Diagnosis of Localized Prostate Cancer. Urology 74:5, 968-971
CrossRef237
S. Mathis, B. Guba, C. Adlbrecht, C. Pramesberger. (2009) Belastungsinkontinenz. Der Urologe 48:11, 1330-1338
CrossRef238
Al V. Taira, Gregory S. Merrick, Robert W. Galbreath, Wayne M. Butler, Kent E. Wallner, Brian S. Kurko, Richard Anderson, Jonathan H. Lief. (2009) Erectile Function Durability Following Permanent Prostate Brachytherapy. International Journal of Radiation Oncology*Biology*Physics 75:3, 639-648
CrossRef239
B Mellado, A Font, A Alcaraz, L A Aparicio, F J G Veiga, J Areal, E Gallardo, N Hannaoui, J R M Lorenzo, A Sousa, P L Fernandez, P Gascon. (2009) Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. British Journal of Cancer 101:8, 1248-1252
CrossRef240
John W. Robinson, Bryan J. Donnelly, Jodi E. Siever, John C. Saliken, Scott D. Ernst, John C. Rewcastle, Kiril Trpkov, Harold Lau, Cheryl Scott, Bejoy Thomas. (2009) A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 115:20, 4695-4704
CrossRef241
U. Lindner, R.A. Weersink, M.A. Haider, M.R. Gertner, S.R.H. Davidson, M. Atri, B.C. Wilson, A. Fenster, J. Trachtenberg. (2009) Image Guided Photothermal Focal Therapy for Localized Prostate Cancer: Phase I Trial. The Journal of Urology 182:4, 1371-1377
CrossRef242
Paul L. Nguyen, Ronald C. Chen, Jack A. Clark, Robert A. Cormack, Marian Loffredo, Elizabeth McMahon, Angela U. Nguyen, W. Warren Suh, Clare M. Tempany, Anthony V. D'Amico. (2009) Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy 8:4, 345-352
CrossRef243
Kien Nguyen, Stephanie Eltz, Sarah J. Drouin, Eva Comperat, François Audenet, Raphaele Renard-Penna, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, François Richard, Olivier Cussenot, Morgan Rouprêt. (2009) Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World Journal of Urology 27:5, 653-658
CrossRef244
Soroush Rais-Bahrami, Manish A. Vira, Louis Potters. (2009) Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Prostate Reports 7:3, 95-101
CrossRef245
David S. Aaronson, Ichiro Yamasaki, Alexander Gottschalk, Joycelyn Speight, I-Chow Hsu, Barby Pickett, Mack Roach, Katsuto Shinohara. (2009) Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU International 104:5, 600-604
CrossRef246
D Wittmann, J E Montie, D A Hamstra, H Sandler, D P Wood. (2009) Counseling patients about sexual health when considering post-prostatectomy radiation treatment. International Journal of Impotence Research 21:5, 275-284
CrossRef247
John F. Anderson, David A. Swanson, Lawrence B. Levy, Deborah A. Kuban, Andrew K. Lee, Rajat Kudchadker, Jack Phan, Teresa Bruno, Steven J. Frank. (2009) Urinary Side Effects and Complications After Permanent Prostate Brachytherapy: The MD Anderson Cancer Center Experience. Urology 74:3, 601-605
CrossRef248
Russell N. Moule, Peter J. Hoskin. (2009) Non-surgical treatment of localised prostate cancer. Surgical Oncology 18:3, 255-267
CrossRef249
Danil V. Makarov, David F. Penson. (2009) Prostate cancer: Quality of life after radiation and androgen deprivation. Nature Reviews Urology 6:9, 477-478
CrossRef250
J C Lloyd, L L Bañez, W J Aronson, M K Terris, J C Presti, C L Amling, C J Kane, S J Freedland. (2009) Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. Prostate Cancer and Prostatic Diseases 12:3, 264-268
CrossRef251
Andre Chow, Erik K. Mayer, Ara W. Darzi, Thanos Athanasiou. (2009) Patient-reported outcome measures: The importance of patient satisfaction in surgery. Surgery 146:3, 435-443
CrossRef252
Scott M. Gilbert. (2009) Prostate cancer: Seminal vesicle sparing: a continuing trend?. Nature Reviews Urology 6:9, 475-476
CrossRef253
Jan Willem Mazel, Philipp Dahm. (2009) Evidence-based urology in practice: intention-to-treat analysis. BJU International 104:5, 582-583
CrossRef254
Roderick C. N. van den Bergh, Marie-Louise Essink-Bot, Monique J. Roobol, Tineke Wolters, Fritz H. Schröder, Chris H. Bangma, Ewout W. Steyerberg. (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115:17, 3868-3878
CrossRef255
K. Hashine, Y. Kusuhara, N. Miura, A. Shirato, Y. Sumiyoshi, M. Kataoka. (2009) Health-related Quality of Life using SF-8 and EPIC Questionnaires after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy. Japanese Journal of Clinical Oncology 39:8, 502-508
CrossRef256
Brian A. Parsons, Simon Evans, Mark P. Wright. (2009) Prostate cancer and urinary incontinence. Maturitas 63:4, 323-328
CrossRef257
Jonathan Bergman, John L. Gore, David F. Penson, Lorna Kwan, Mark S. Litwin. (2009) Erectile Aid Use by Men Treated for Localized Prostate Cancer. The Journal of Urology 182:2, 649-654
CrossRef258
Patrick Teloken, Guilherme Mesquita, Francesco Montorsi, John Mulhall. (2009) Post-Radical Prostatectomy Pharmacological Penile Rehabilitation: Practice Patterns Among the International Society for Sexual Medicine Practitioners. Journal of Sexual Medicine 6:7, 2032-2038
CrossRef259
Alexandre Peltier, Roland van Velthoven, Thierry Roumeguère. (2009) Current management of erectile dysfunction after cancer treatment. Current Opinion in Oncology 21:4, 303-309
CrossRef260
Ryan C. Hedgepeth, Jessica Labo, LingLing Zhang, David P. Wood. (2009) Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy. The Journal of Urology 182:1, 221-228
CrossRef261
Ferran Guedea, Montse Ferrer. (2009) Spanish Researchers at the Forefront of Clinical Investigation: The case of quality of life in prostate cancer. Clinical and Translational Oncology 11:7, 403-404
CrossRef262
, Ferran Guedea, Montserrat Ferrer, Joan Pera, Ferrán Aguiló, Anna Boladeras, José Francisco Suárez, Oriol Cunillera, Ferrán Ferrer, Yolanda Pardo, Evelyn Martínez, Montse Ventura. (2009) Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. Clinical and Translational Oncology 11:7, 470-478
CrossRef263
Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun, Pierre I. Karakiewicz, Andrea Salonia, Marco Bianchi, Andrea Cestari, Giorgio Guazzoni, Patrizio Rigatti, Francesco Montorsi. (2009) Prediction of sexual function after radical prostatectomy. Cancer 115:S13, 3150-3159
CrossRef264
P. J. Goodwin, S. S. Sridhar. (2009) Health-Related Quality of Life in Cancer Patients--More Answers but Many Questions Remain. JNCI Journal of the National Cancer Institute 101:12, 838-839
CrossRef265
J. L. Gore, L. Kwan, S. P. Lee, R. E. Reiter, M. S. Litwin. (2009) Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer. JNCI Journal of the National Cancer Institute 101:12, 888-892
CrossRef266
Supriya G. Mohile, Karen Mustian, Kathryn Bylow, William Hall, William Dale. (2009) Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology 70:3, 235-255
CrossRef267
Patrick J. Bastian, Ballentine H. Carter, Anders Bjartell, Michael Seitz, Peter Stanislaus, Francesco Montorsi, Christian G. Stief, Fritz Schröder. (2009) Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. European Urology 55:6, 1321-1332
CrossRef268
Richard Lee, Alexis E. Te, Steven A. Kaplan, Jaspreet S. Sandhu. (2009) Temporal Trends in Adoption of and Indications for the Artificial Urinary Sphincter. The Journal of Urology 181:6, 2622-2627
CrossRef269
J Antonelli, S J Freedland, L W Jones. (2009) Exercise therapy across the prostate cancer continuum. Prostate Cancer and Prostatic Diseases 12:2, 110-115
CrossRef270
Martin G. Sanda. (2009) Editorial Comment. Urology 73:6, 1340-1341
CrossRef271
Neil E. Fleshner, Nathan Lawrentschuk. (2009) Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers. Urology 73:5, S21-S27
CrossRef272
Leonard G. Gomella, James Johannes, Edouard J. Trabulsi. (2009) Current Prostate Cancer Treatments: Effect on Quality of Life. Urology 73:5, S28-S35
CrossRef273
Walter R Parker, Jeffery S Montgomery, David P Wood. (2009) Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?. Current Opinion in Urology 19:3, 303-308
CrossRef274
Michael Pinkawa, Branka Asadpour, Marc D. Piroth, Bernd Gagel, Sandra Nussen, Mareike Kehl, Holger Borchers, Gerhard Jakse, Michael J. Eble. (2009) Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer – a matched-pair comparison. Radiotherapy and Oncology 91:2, 225-231
CrossRef275
Evanguelos Xylinas, Sarah J. Drouin, Eva Comperat, Christophe Vaessen, Raphaële Renard-Penna, Vincent Misrai, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, François Richard, Olivier Cussenot, Morgan Roupret. (2009) Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU International 103:9, 1173-1178
CrossRef276
Nina Knoll, Silke Burkert, Jürgen Kramer, Jan Roigas, Oliver Gralla. (2009) Relationship Satisfaction and Erectile Functions in Men Receiving Laparoscopic Radical Prostatectomy: Effects of Provision and Receipt of Spousal Social Support. Journal of Sexual Medicine 6:5, 1438-1450
CrossRef277
Gerald L. Andriole. (2009) Introduction. Urology 73:5, S1-S3
CrossRef278
Patrick C. Walsh. (2009) 2008 Whitmore Lecture: Radical prostatectomy—where we were and where we are going. Urologic Oncology: Seminars and Original Investigations 27:3, 246-250
CrossRef279
Gerald L. Andriole. (2009) Overview of Pivotal Studies for Prostate Cancer Risk Reduction, Past and Present. Urology 73:5, S36-S43
CrossRef280
Soroush Rais-Bahrami, Manish A. Vira, Louis Potters. (2009) Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Urology Reports 10:3, 187-193
CrossRef281
Gautam Jayram, Scott E Eggener. (2009) Patient selection for focal therapy of localized prostate cancer. Current Opinion in Urology 19:3, 268-273
CrossRef282
Stanley L. Liauw, Janine Fricano, David Correa, Ralph R. Weichselbaum, Ashesh B. Jani. (2009) Dose-escalated radiation therapy for intermediate-risk prostate cancer. Cancer 115:8, 1784-1790
CrossRef283
Edan Y. Shapiro, Soroush Rais-Bahrami, Carol Morgenstern, Barbara Napolitano, Lee Richstone, Louis Potters. (2009) Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy. The Journal of Urology 181:4, 1665-1671
CrossRef284
Patrick E. Teloken, Marilyn Parker, Najeeb Mohideen, John P. Mulhall. (2009) Predictors of Response to Sildenafil Citrate Following Radiation Therapy for Prostate Cancer. Journal of Sexual Medicine 6:4, 1135-1140
CrossRef285
Per Fransson, Jo-Åsmund Lund, Jan-Erik Damber, Olbjörn Klepp, Fredrik Wiklund, Sophie Fosså, Anders Widmark. (2009) Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. The Lancet Oncology 10:4, 370-380
CrossRef286
Martin G Sanda. (2009) Live longer but not better … yet. The Lancet Oncology 10:4, 313-314
CrossRef287
John M. Fitzpatrick, Claude Schulman, Alexandre R. Zlotta, Fritz H. Schröder. (2009) Prostate cancer: a serious disease suitable for prevention. BJU International 103:7, 864-870
CrossRef288
Steven J. Frank, Lawrence B. Levy, Deborah A. Kuban, Andrew K. Lee, Rajat J. Kudchadker, Teresa L. Bruno, Marco van Vulpen, David A. Swanson. (2009) Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With 125Iodine Brachytherapy. The Journal of Urology 181:4, 1658-1664
CrossRef289
Barrie R. Cassileth, Jyothirmai Gubili, K. Simon Yeung. (2009) Integrative medicine: complementary therapies and supplements. Nature Reviews Urology 6:4, 228-233
CrossRef290
Diana D. Jeffery, Janice P. Tzeng, Francis J. Keefe, Laura S. Porter, Elizabeth A. Hahn, Kathryn E. Flynn, Bryce B. Reeve, Kevin P. Weinfurt. (2009) Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee. Cancer 115:6, 1142-1153
CrossRef291
D Wittmann, L Northouse, S Foley, S Gilbert, D P Wood, R Balon, J E Montie. (2009) The psychosocial aspects of sexual recovery after prostate cancer treatment. International Journal of Impotence Research 21:2, 99-106
CrossRef292
M. Gosney. (2009) General Care of the Older Cancer Patient. Clinical Oncology 21:2, 86-91
CrossRef293
Jay P. Ciezki. (2009) Brachytherapy for Localized Prostate Cancer. Urology 73:3, 473-475
CrossRef294
David W McDermott, Martin G Sanda. (2009) Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. Nature Clinical Practice Urology 6:3, 124-125
CrossRef295
Irene M. Lips, Carla H. van Gils, Uulke A. van der Heide, Arto E. Boeken Kruger, Marco van Vulpen. (2009) Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU International 103:6, 762-767
CrossRef296
Ian M. Thompson, Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, Gary Miller, Dean Troyer, Edward Messing, Jeffrey Forman, Joseph Chin, Gregory Swanson, Edith Canby-Hagino, E. David Crawford. (2009) Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. The Journal of Urology 181:3, 956-962
CrossRef297
Andrew J. Stephenson, J. Stephen Jones, Adrian V. Hernandez, Jay P. Ciezki, Michael C. Gong, Eric A. Klein. (2009) Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels. European Urology 55:3, 610-616
CrossRef298
Barnett S. Kramer, Jennifer Miller Croswell. (2009) Cancer Screening: The Clash of Science and Intuition *. Annual Review of Medicine 60:1, 125-137
CrossRef299
Leonard Glickman, Guilherme Godoy, Herbert Lepor. (2009) Changes in Continence and Erectile Function Between 2 and 4 Years After Radical Prostatectomy. The Journal of Urology 181:2, 731-735
CrossRef300
Andrea Gallina, Andrea Salonia, Alberto Briganti, Nazareno Suardi, Federico Dehò, Giuseppe Zanni, Antonino Saccà, Firas Abdollah, Andrea Cestari, Giorgio Guazzoni, Patrizio Rigatti, Francesco Montorsi. (2009) Prevention and Management of Postprostatectomy Erectile Dysfunction. European Urology Supplements 8:2, 80-87
CrossRef301
Eric Huyghe, Dawen Sui, Evan Odensky, Leslie R. Schover. (2009) Needs Assessment Survey to Justify Establishing a Reproductive Health Clinic at a Comprehensive Cancer Center. Journal of Sexual Medicine 6:1, 149-163
CrossRef302
Patrick J. Bastian. (2009) Editorial Comment on: Nerves at the Ventral Prostatic Capsule Contribute to Erectile Function: Initial Electrophysiological Assessment in Humans. European Urology 55:1, 154-155
CrossRef303
Floortje Mols, Pascal Stijns, Bram Dankaart, Saskia Houterman, Ad Vingerhoets, Ad Hendrikx. (2009) Health-Related Quality of Life in I-125 Prostate Brachytherapy Patients Treated with and without Volume-Reducing Hormone Therapy: Results of a Short-Term Prospective Study. Journal of Endourology 23:1, 153-160
CrossRef304
(2008) Management of Prostate Cancer. New England Journal of Medicine 359:24, 2605-2609
Full Text305
Tracy P. Marien, Herbert Lepor. (2008) Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?. BJU International 102:11, 1581-1584
CrossRef306
Cheri L. Van Patten, Johan G. de Boer, Emma S. Tomlinson Guns. (2008) Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. The Journal of Urology 180:6, 2314-2322
CrossRef307
C. Schäfer. (2008) Längerfristige Lebensqualität bei lokal begrenztem Prostatakarzinom. Der Onkologe 14:12, 1276-1277
CrossRef308
Martin G. Sanda. (2008) Editorial Comment. The Journal of Urology 180:6, 2422
CrossRef309
Wesley M. White, Natalia Sadetsky, W. Bedford Waters, Peter R. Carroll, Mark S. Litwin. (2008) Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database. The Journal of Urology 180:6, 2409-2414
CrossRef310
Florian R. Schroeck, Craig F. Donatucci, Emily C. Smathers, Leon Sun, David M. Albala, Thomas J. Polascik, Judd W. Moul, Tracey L. Krupski. (2008) Defining potency: A comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer 113:10, 2687-2694
CrossRef311
Mark Soloway. (2008) A 43-year-old African American man with low-risk prostate cancer. Current Urology Reports 9:6, 437-440
CrossRef312
Kevin S. Oh, Howard M. Sandler. (2008) Second Malignancies After Radiotherapy for Prostate Cancer: Keeping Perspective. Urology 72:5, 971-973
CrossRef313
Mack Roach. (2008) Editorial Comment. The Journal of Urology 180:5, 2009-2010
CrossRef314
Joseph A. Smith. (2008) Radical prostatectomy for low risk carcinoma of the prostate. World Journal of Urology 26:5, 443-446
CrossRef315
Gerald F. Riley, Joan L. Warren, Arnold L. Potosky, Carrie N. Klabunde, Linda C. Harlan, Michael B. Osswald. (2008) Comparison of Cancer Diagnosis and Treatment in Medicare Fee-for-Service and Managed Care Plans. Medical Care 46:10, 1108-1115
CrossRef316
(2008) Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. New England Journal of Medicine 359:2, 200-202
Full Text317
Steven B Zeliadt, Scott D Ramsey, Arnold L Potosky, Neeraj K Arora, David K Blough, Ingrid Oakley-Girvan, Ann S Hamilton, Stephen K Van Den Eeden, David F Penson. (2008) Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. The Patient: Patient-Centered Outcomes Research 1:3, 189-200
CrossRef318
(2008) Health-related quality-of-life changes in prostate-cancer survivors. Nature Clinical Practice Urology 5:6, 290-290
CrossRef
- Letters
